 | Hiroshi Fujishima |
Prominent publications by Hiroshi Fujishima
KOL Index score: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Also Ranks for: Ocular Surface | eyes corneal ulcers | atopic patients | brush cytology | akc vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Also Ranks for: Dry Eye Disease | coherence tomography | tear meniscus height | sensitivity specificity | strip meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Also Ranks for: Oxidative Stress | akc patients | surface disease | inflammatory cells | 5 females |
KOL Index score: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Also Ranks for: Vkc Akc | allergic conjunctivitis | topical steroids | 1 month | objective signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Also Ranks for: Atopic Keratoconjunctivitis | ocular surface | patients akc | muc5ac muc16 | goblet cell |
KOL Index score: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Also Ranks for: Ocular Surface | atopic keratoconjunctivitis | patients akc | eyes vkc | brush cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Also Ranks for: Atopic Keratoconjunctivitis | ocular surface | brush cytology | corneal sensitivity | epithelial mucins |
KOL Index score: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Also Ranks for: Intraocular Lens | visual acuity | 1cu iol | cataract surgery | amplitude accommodation |
KOL Index score: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Also Ranks for: Receptor Crth2 | chemotaxis eosinophils | allergic conjunctivitis | pgd2dependent migration | homologous molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Also Ranks for: Severe Allergic Conjunctivitis | tacrolimus ophthalmic | objective signs | corneal involvement | clinical trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Also Ranks for: Conjunctival Fibroblasts | vascular endothelial | growth factor | vegf concentration | akc vkc |
KOL Index score: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Also Ranks for: Intraocular Lens | thinoptx iol | phacoemulsification implantation | visual acuity | 6 months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Also Ranks for: Ocular Surface | topical cyclosporine | eye patients | chronic graft | host disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Also Ranks for: Allergic Conjunctivitis | tears patients | vkc gpc | normal controls | linked immunosorbent |
Hiroshi Fujishima: Influence Statistics
| Concept | World rank |
|---|---|
| release inhibitor purpose | #1 |
| patients capilia | #1 |
| severe akc | #1 |
| conjunctivitis seasonal | #1 |
| 01 tacrolimus eye | #1 |
| solution ocular | #1 |
| il4 tranilast | #1 |
| epithelium disorders | #1 |
| diseases tear | #1 |
| commercial washing solution | #1 |
| akc compared | #1 |
| fourgraded severity | #1 |
| dha western blotting | #1 |
| objective findings conclusions | #1 |
| eye allerwatch | #1 |
| samples allergic conjunctivitis | #1 |
| nsaids systemic control | #1 |
| adenovirus capilia | #1 |
| tacrolimus eye drops | #1 |
| akc methods | #1 |
| fluorometholone 002 | #1 |
| allergic conjunctivitis | #1 |
| 01 ophthalmic solution | #1 |
| conjunctivitis conjunctival | #1 |
| suspension treating | #1 |
| commercial eyewash solutions | #1 |
| tears allergic patients | #1 |
| akc treatment | #1 |
| production conjunctival fibroblasts | #1 |
| keratoconjunctivitis male | #1 |
| bromfenac sodium | #1 |
| positivity rate allerwatch | #1 |
| akc | #1 |
| clinical signs akc | #1 |
| tacrolimus eye drop | #1 |
| instillation bromfenac | #1 |
| dscg bf | #1 |
| corneal epithelium disorders | #1 |
| akc vernal | #1 |
| fml administered | #1 |
| higher capilia | #1 |
| capilia adeno | #1 |
| keratoconjunctivitis akc | #1 |
| epithelial pge2 | #1 |
| tacrolimus eye | #1 |
| dscg 005 | #1 |
| allergic tranilast | #1 |
| keratoconjunctivitis background | #1 |
| fml 002 | #1 |
| bak epithelium disorders | #1 |
| efficacy bromfenac sodium | #1 |
| severe binocular conjunctivitis | #1 |
| rsv conjunctival | #1 |
| drops elicited | #1 |
| pcr eotaxin1 | #1 |
| immunocytochemical study rtpcr | #1 |
| concomitant bf | #1 |
| fumarate dexamethasone | #1 |
| rapid ophthalmic | #1 |
| cox2 conjunctival | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| tacrolimus eye treatment | #1 |
| bromfenac sodium treatment | #1 |
| allergic enzyme | #1 |
| allerwatch diagnostic accuracy | #1 |
| eyewash solution bak | #1 |
| allerwatch higher | #1 |
| 3 months signs | #1 |
| vkc april | #1 |
| subjective ocular symptoms | #1 |
| scores hyperemia | #1 |
| vkc akc | #1 |
| eotaxin1 production | #1 |
| commercial eyewash | #1 |
| allergic conjunctivitis efficacy | #1 |
| tacrolimus ophthalmic solution | #1 |
| production ketotifen fumarate | #1 |
| hundredandseventy eyes | #1 |
| allerwatch tests | #1 |
| tacrolimus ophthalmic | #1 |
| 0001 allerwatch | #1 |
| fml dscg | #1 |
| efficacy fml | #1 |
| il4 causing | #1 |
| akc allergic | #1 |
| exacerbation vkc | #1 |
| tears conjunctival fibroblasts | #1 |
| conjunctivitis helper | #1 |
| conjunctival fibroblasts | #1 |
| eye surface years | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| atopic keratoconjunctivitis | #1 |
| cedrus conjunctivitis | #1 |
| patients akc | #1 |
| patients severe conjunctivitis | #1 |
| incubated interleukin | #1 |
| il4 tear | #1 |
| tranilast dexamethasone | #1 |
| sodium ophthalmic solution | #1 |
| adeno eye | #1 |
| antagonists child conjunctivitis | #1 |
| eyewash solution | #1 |
| conjunctival fibroblasts production | #1 |
| tranilast production | #1 |
| vkc conclusions | #1 |
| cd3 cd4bearing cells | #1 |
| inhibition eotaxin1 | #1 |
| itchy sensation | #1 |
| conclusions objective assessments | #1 |
| higher akc | #1 |
| postoperative conjunctivitis | #1 |
| selective chemotactic effects | #1 |
| scleritis tacrolimus | #1 |
| conjunctivitis enrolled | #1 |
| eyewash | #1 |
| action child conjunctivitis | #1 |
| bromfenac sodium bf | #1 |
| bromobenzenes conjunctivitis | #1 |
| drop levocabastine | #1 |
| akc tear | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| experience 01 | #1 |
| keratoconjunctivitis vernal | #1 |
| severe conjunctivitis eyes | #1 |
| initiating tacrolimus | #1 |
| pge2 human conjunctival | #1 |
| bf fml | #1 |
| akc vkc | #1 |
| child conjunctivitis | #1 |
| tacrolimus tears | #1 |
| eyewash solutions | #1 |
| bak epithelium | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| production tranilast | #1 |
| signs palpebral | #1 |
| fml patients | #1 |
| vkc cases | #1 |
| binocular conjunctivitis | #1 |
| instillation symptoms | #1 |
| conjunctivitis including | #1 |
| eyebon eye | #1 |
| radioimmunoassay il4 | #1 |
| stat6results | #1 |
| dscg symptoms | #1 |
| allergic corneal | #1 |
| conjunctival cedar | #1 |
| characterized conjunctival | #1 |
| bf concomitantly | #1 |
| allergic docosahexaenoic | #1 |
| akc administration | #1 |
| 10 objective signs | #1 |
| selected fml | #1 |
| allergens levocabastine | #1 |
| patients allergic conjunctivitis | #1 |
| ketotifen fumarate dexamethasone | #1 |
| allerwatch positivity rate | #1 |
| atopic keratoconjunctivitis akc | #1 |
| severity objective signs | #1 |
| cases severe conjunctivitis | #1 |
| conjunctivitis concomitantly | #1 |
| 12 patients akc | #1 |
| eye wash | #1 |
| suppressing pge2 production | #1 |
| ocular allergic diseases | #1 |
| talymus | #1 |
| primary human conjunctival | #1 |
| artificial tears positive | #1 |
| ige allerwatch | #1 |
| test capilia | #1 |
| levocabastine artificial | #1 |
| allergic conjunctivitis drop | #1 |
| capilia adeno eye | #1 |
| dha il4 | #1 |
| tears allergic | #1 |
| conjunctivitis japanese | #1 |
| include conjunctival | #1 |
| patients atopic keratoconjunctivitis | #1 |
| allergenmediated conjunctivitis | #1 |
| itching levocabastine | #1 |
| therapy levocabastine | #1 |
| eyewash solutions bak | #1 |
| keratocytes tnfα | #1 |
| prostaglandin tears | #1 |
| allergic postoperative | #1 |
| eye itching | #1 |
| sodium allergic | #1 |
| systemic control pain | #1 |
| dscg fml | #1 |
| tranilast eotaxin1 | #1 |
| sodium bf | #1 |
| conjunctivitis aims | #1 |
| hyperemia pain | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| solution allergic | #1 |
| tacrolimus ophthalmic suspension | #1 |
| improvement combinedtreatment | #1 |
| washing allergens | #1 |
| adult cedrus conjunctivitis | #1 |
| eyebon | #1 |
| initiation tacrolimus treatment | #1 |
| ded anti | #1 |
| satisfaction suspensions | #1 |
| rate allerwatch | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| akc patients | #1 |
| adverse events scores | #1 |
| conjunctivitis treated | #1 |
| levocabastine artificial tears | #1 |
| eye fml | #1 |
| accuracy conjunctivitis | #1 |
| compared fluorometholone | #1 |
| iop akc | #1 |
| extents corneal | #2 |
| japan akc | #2 |
| correlation fluorescein | #2 |
| severity eyelid | #2 |
| lower conjunctival sacs | #2 |
| bovine entericcoated lactoferrin | #2 |
| corneal lesions | #2 |
| corneal complications height | #2 |
| corneal temperature patients | #2 |
| tarsal brush | #2 |
| epinastine ophthalmic solution | #2 |
| conjunctivitis representative | #2 |
| inflammatory child child | #2 |
| drops hyperemia | #2 |
| formation akc | #2 |
| giant papillary formation | #2 |
| normal blinking patients | #2 |
| akc sac patients | #2 |
| treatment tear | #2 |
| conjunctivitis proliferative | #2 |
| tacrolimus topical | #2 |
| limbal swelling | #2 |
| severe allergic conjunctivitis | #2 |
| lactoferrin 01 | #2 |
| diabetic patients ono2235 | #2 |
| largescale study protocol | #2 |
| corneal epithelial signs | #2 |
| including akc | #2 |
| akc treated | #2 |
| adjuvant betamethasone | #2 |
| brush cytology samples | #2 |
| aided papillary | #2 |
| allergic endophthalmitis | #2 |
| epitheliopathy patients | #2 |
| conjunctival injection reduction | #2 |
| oral aldose | #2 |
| bovine placebo | #2 |
| pollutants prevalence | #2 |
| keratoconjunctivitis age | #2 |
| prevalence akc | #2 |
| conjunctiva bulbar | #2 |
| mmc 7 eyes | #2 |
| akc 6 | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| olopatadine visit | #2 |
| cedrus conjunctiva | #2 |
| edema corneal damage | #2 |
| eyelid elasticity | #2 |
| environmental studies prevalence | #2 |
| suspension talymus | #2 |
| air pollutants prevalence | #2 |
| skin elasticity patients | #2 |
| simple papillary resection | #2 |
| ensured proving | #2 |
| akc patients correlation | #2 |
| total signs symptoms | #2 |
| immunoregulatory effects study | #2 |
| treated bromfenac | #2 |
| serum allergic parameters | #2 |
| patients corneal ulcers | #2 |
| conjunctiva papillary | #2 |
| akc 10 | #2 |
| shield ulcers patients | #2 |
| epitheliopathy shield | #2 |
| baseline papillae | #2 |
| ecp levels akc | #2 |
| severity corneal damage | #2 |
| reported eotaxin | #2 |
| cornea grading | #2 |
| regrowth 7 eyes | #2 |
| oral ari ono2235 | #2 |
| deqs tear | #2 |
| evaluate superiority | #2 |
| conjunctivitis condition | #2 |
| endpoint itching scale | #2 |
| olopatadine ocular | #2 |
| patients severe akc | #2 |
| allergic conjunctivitis akc | #2 |
| ceramide gel application | #2 |
| epitheliopathy steroids | #2 |
| objective signs baseline | #2 |
| sem575 clinical | #2 |
| conjunctiva atopic | #2 |
| elasticity severity | #2 |
| tacrolimus tonometry | #2 |
| solutions japan | #2 |
| diagnosis ensured | #2 |
| control subjects eyes | #2 |
| neutrophils brush | #2 |
| betamethasone glaucoma | #2 |
| papillae limbus | #2 |
| bromfenac ophthalmic solution | #2 |
| mmc aided | #2 |
| akc 1 | #2 |
| giant papillae formation | #2 |
| ecp severity markers | #2 |
| refractory allergic | #2 |
| disease antiallergic | #2 |
| neutrophils corneal damage | #2 |
| corneal findings | #2 |
| diathesis subjective | #2 |
| papillary excision | #2 |
| csa akc | #2 |
| eosinophils corneal damage | #2 |
| 18 akc | #2 |
| lessen steroid | #2 |
| conjunctivitis 10 | #2 |
| cutometer sem575 | #2 |
| month eyewash | #2 |
| patients shield ulcers | #2 |
| tacrolimus lessen | #2 |
| tacrolimus detection | #2 |
| epitheliopathy corneal | #2 |
| correlation eosinophils | #2 |
| 2helper cell | #2 |
| tear ige correlation | #2 |
| score topical | #2 |
| detected akc | #2 |
| recurrence corneal complications | #2 |
| eyelid atopic | #2 |
| dryness scores | #2 |
| asthma heart diseases | #2 |
| concomitantly abovementioned | #2 |
| excision cobblestonelike papillae | #2 |
| effects tacrolimus | #2 |
| representative subjective | #2 |
| lid skin | #2 |
| total clinical signs | #2 |
| epitheliopathy refractory | #2 |
| talymus akc | #2 |
| tears akc | #2 |
| regrowth papillae | #2 |
| effects topical tacrolimus | #2 |
| treatment atopic blepharitis | #2 |
| cac test | #2 |
| drop concomitantly | #2 |
| akc aureus | #2 |
| test papillae | #2 |
| decrease corneal temperature | #2 |
| epinastine 15 minutes | #2 |
| papilla accompanied | #2 |
| steroids epitheliopathy | #2 |
| production specular | #2 |
| conjunctivitis adolescent | #2 |
| folliculosis papillae | #2 |
| drops refractory | #2 |
| akc allergic diagnosis | #2 |
| score adjustments | #2 |
| correlation neutrophils | #2 |
| bromfenac sodium bromfenac | #2 |
| aureussecreted enterotoxins | #2 |
| hyperemia lacrimation | #2 |
| superiority epinastine | #2 |
| severity corneal lesions | #2 |
| swelling folliculosis | #2 |
| based papillae | #2 |
| excision cobblestone | #2 |
| methods thirtysix patients | #2 |
| formation palpebral | #2 |
| sodium ophthalmic | #2 |
| conventional antiallergic drugs | #2 |
| steroid metaregression | #2 |
| ulcer complain | #2 |
| corneal recurrences | #2 |
| adjuvant fluorometholone | #2 |
| cobblestonelike papillae | #2 |
| patients tacrolimus eye | #2 |
| 062 tear | #2 |
| female humans akc | #2 |
| suspension lactoferrin | #2 |
| olopatadine cedar | #2 |
| placebo noninferiority | #2 |
| edema height | #2 |
| allergic conjunctivitis ige | #2 |
| severity corneal complications | #2 |
| akc young adult | #2 |
| eyes betamethasone | #2 |
| elasticity eyelid | #2 |
| simple resection regrowth | #2 |
| akc levels | #2 |
| 95 adjuvant betamethasone | #2 |
| muc16 immunohistochemistry | #2 |
| japan topical | #2 |
| seasonal allergic conjunctivitis | #2 |
| conjunctival injection edema | #2 |
| resolution thermography | #2 |
| adjuvant fluorometholone 95 | #2 |
| allergy accompanied | #2 |
| tacrolimus iop | #2 |
| conjunctivitis retrospective | #2 |
| premedication combined | #2 |
| treatment total signs | #2 |
| efficacy severe akc | #2 |
| papillae mucous discharge | #2 |
| patients shield | #2 |
| sac healthy | #2 |
| tears thiazolidines | #2 |
| period rhodanine | #2 |
| corneal damage height | #2 |
| signs blood concentration | #2 |
| drops conjunctival | #2 |
| 001 brush | #2 |
| japan topical tacrolimus | #2 |
| vkc 5 | #2 |
| factor vkc | #2 |
| vkc japan | #2 |
| papillae preventing | #2 |
| adjustments epitheliopathy | #2 |
| papillae severe | #2 |
| epitheliopathy score | #2 |
| corneal ulcers patients | #2 |
| signs decreased | #2 |
| accompanied subjective | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| akc adult | #2 |
| ketotifen dexamethasone | #2 |
| tacrolimus shield | #2 |
| topical tacrolimus combination | #2 |
| atopic blepharitis | #2 |
| eyes 824 | #2 |
| study designopen cohort | #2 |
| post cataract surgery | #2 |
| nonpreserved eyewash solution | #2 |
| unpaired ttest talymus | #2 |
| height papillae | #2 |
| eyelid skin elasticity | #2 |
| benzophenones bromobenzenes | #2 |
| elevation tacrolimus | #2 |
| allergic conjunctivitis levocabastine | #2 |
| treatment ecp concentrations | #2 |
| fluorescein conjunctival injection | #2 |
| conjunctivitis purpose | #2 |
| pge2 tears | #2 |
| ophthalmic nsaid | #2 |
| conclusions bromfenac | #2 |
| administered elf | #2 |
| corneal damage patients | #2 |
| allergic diagnosis | #2 |
| adjustments epitheliopathy score | #2 |
| proliferative called | #2 |
| corneal lesions regrowth | #2 |
| rhodanine rose | #2 |
| atopic diagnostic techniques | #2 |
| metaregression analysis glaucoma | #2 |
| administration specular | #2 |
| topical antiallergic agents | #2 |
| treatment shield ulcer | #2 |
| tacrolimus published data | #2 |
| nonwash | #2 |
| blepharitis ceramides | #2 |
| papillae akc | #2 |
| bromfenac effective | #2 |
| iop topical steroids | #2 |
| oral ari administration | #2 |
| conjunctival corneal cells | #2 |
| scores papillary | #2 |
| eyewash 005 | #2 |
| defined conjunctival | #2 |
| conjunctival findings severity | #2 |
| sem575 quantitatively | #2 |
| tacrolimus 1 month | #2 |
| tear film layer | #2 |
| noninferiority olopatadine | #2 |
| keratoconjunctivitis corneal | #2 |
| lesions allergic | #2 |
| cytodiagnosis dermatitis | #2 |
| akc 10 eyes | #2 |
| improvement vital staining | #2 |
| scores tacrolimus | #2 |
| administered elf bovine | #2 |
| lacrimation objective | #2 |
| ari ocular | #2 |
| sodium bromfenac | #2 |
| tacrolimus 12 weeks | #2 |
| improvement corneal fluorescein | #2 |
| recurrence corneal lesions | #2 |
| eyelid atopic dermatitis | #2 |
| oral ari | #2 |
| tacrolimus detection limit | #2 |
| papillary formation | #2 |
| epinastine superiority | #2 |
| corneal epitheliopathy score | #2 |
| mucous discharge severity | #2 |
| complain foreign | #2 |
| solution epinastine | #2 |
| drop steroid | #2 |
| mucin analyzed | #2 |
| brush cytology patients | #2 |
| selected bf | #2 |
| plaques 791 | #2 |
| sem575 | #2 |
| ocular surface mucin | #2 |
| dermatitis remission | #2 |
| 1 month tacrolimus | #2 |
| conjunctivitis epitheliopathy | #2 |
| akc adolescent | #2 |
| corneal epitheliopathy | #2 |
| lnfs nbs | #3 |
| tears treatment | #3 |
| vkc papillae | #3 |
| 005 collagens | #3 |
| papillae upper | #3 |
| conjunctivitis lymphocytes | #3 |
| superficial cells conjunctiva | #3 |
| infrared radiation thermography | #3 |
| dibenzoxepins female | #3 |
| hydrochloride 01 | #3 |
| akc higher | #3 |
| pm25 allergic | #3 |
| antibody titers ade | #3 |
| erosions refractory | #3 |
| vkc long | #3 |
| metry dfna | #3 |
| 12 akc | #3 |
| il1beta th2 cytokines | #3 |
| pm25 outpatient attendance | #3 |
| cooling cataract | #3 |
| inflammation mmc | #3 |
| dfna control | #3 |
| cell flare count | #3 |
| mmc excision | #3 |
| elisa histamine | #3 |
| tears adolescent | #3 |
| treatment strip meniscometry | #3 |
| tear periostin | #3 |
| superior limbic portion | #3 |
| fluorescein glycyrrhizic | #3 |
| outpatient attendance july | #3 |
| treatment vernal | #3 |
| sde controls | #3 |
| 01 bromfenac | #3 |
| eyes allergic | #3 |
| hyperemia allergic | #3 |
| cases vkc | #3 |
| traumatic swelling | #3 |
| akc atopic dermatitis | #3 |
| cholinergic treatment response | #3 |
| normal controls collagens | #3 |
| patching patient | #3 |
| nbs subbasal | #3 |
| commercial washing | #3 |
| papillae morphometric | #3 |
| akc confocal microscopy | #3 |
| child conjunctiva | #3 |
| patching case | #3 |
| outpatient visits july | #3 |
| differences dfna | #3 |
| diabetic corneal disease | #3 |
| histamine cedar pollen | #3 |
| 1 month initiation | #3 |
| temperature evaluate | #3 |
| decline corneal | #3 |
| tryptase conjunctiva | #3 |
| cases vernal | #3 |
| membrane uncontrollable | #3 |
| dfna eye | #3 |
| epinastine placebo | #3 |
| allergic corneal diseases | #3 |
| akc eyes | #3 |
| injections keratoconjunctivitis | #3 |
| interleukin4 histamine | #3 |
| periostin topical | #3 |
| induced inflammation lenses | #3 |
| measurements schirmer | #3 |
| ecp severity | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| severe allergy patients | #3 |
| dry eye eye | #3 |
| tear periostin biomarker | #3 |
| conjunctivitis benzamidines | #3 |
| proving type | #3 |
| thermography evaluate | #3 |
| fibronectin normal controls | #3 |
| surgery dfna | #3 |
| ari corneal | #3 |
| allergic patients conjunctivitis | #3 |
| existence par2 | #3 |
| lacrimal punctal occlusion | #3 |
| scale tmh | #3 |
| 22 eyes 100 | #3 |
| formation vkc | #3 |
| reaction conjunctiva | #3 |
| akc persistent | #3 |
| vkc relevant factor | #3 |
| portable recordable | #3 |
| laser cellflaremetry | #3 |
| allergic conjunctivitis aged | #3 |
| lower muc5ac | #3 |
| 21 akc | #3 |
| flare metry | #3 |
| allergic corneal ulcer | #3 |
| par2 benzamidines blotting | #3 |
| aged biological dressings | #3 |
| akc biomarkers | #3 |
| 21 akc patients | #3 |
| technique 2 eyes | #3 |
| dscg administration | #3 |
| ophthalmic solution placebo | #3 |
| conjunctiva allergic | #3 |
| sdedry eye | #3 |
| 12 akc patients | #3 |
| cytology impression | #3 |
| antiallergic eye drop | #3 |
| 01 ophthalmic | #3 |
| healed amniotic | #3 |
| tissue remodeling exacerbation | #3 |
| drop selected | #3 |
| signs remission | #3 |
| rose bengal akc | #3 |
| aged elisa | #3 |
| weekly average values | #3 |
| ophthalmic solution nsaid | #3 |
| akc tear periostin | #3 |
| periostin comorbidities | #3 |
| vkc sac | #3 |
| vkc differences | #3 |
| ulcers eyes | #3 |
| fluorescein scale | #3 |
| ulcer persistent | #3 |
| drops treat | #3 |
| vkc eyes | #3 |
| formation vernal | #3 |
| patients pilocarpine tablets | #3 |
| association outpatient attendance | #3 |
| underwent periodic | #3 |
| periostin akc | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| scored global | #3 |
| prophylaxis conjunctival | #3 |
| strip meniscometry testing | #3 |
| aureus akc patients | #3 |
| operation eye | #3 |
| diclofenac eye drops | #3 |
| akc periostin | #3 |
| outpatient visits august | #3 |
| histamine cedar | #3 |
| corneal ulceration role | #3 |
| corneal complications1 | #3 |
| benzamidine par2 | #3 |
| conjunctivitis pm25 | #3 |
| ebv ade | #3 |
| tryptase increases | #3 |
| corneal akc | #3 |
| superior keratoconjunctiva | #3 |
| diseases acds | #3 |
| vkc fibronectin | #3 |
| rtpcr par2 | #3 |
| adedry eye | #3 |
| pollen postoperative | #3 |
| techniques conjunctivitis | #3 |
| local tear deficiency | #3 |
| tear il13 | #3 |
| fibronectin vkc | #3 |
| conjunctival fibroblasts tryptase | #3 |
| allergic cornea | #3 |
| cultured tryptase | #3 |
| giant papilla | #3 |
| central corneal temperature | #3 |
| nonpreserved artificial tears | #3 |
| interleukin4 tacrolimus | #3 |
| mmc authors | #3 |
| laser flarecellmetry | #3 |
| tmh measurement | #3 |
| topical cyclosporine 01 | #3 |
| insufficient tear | #3 |
| severe allergic patients | #3 |
| treatment skin elasticity | #3 |
| immunosuppressive eye | #3 |
| oct tmh | #3 |
| mmcaided papillary resection | #3 |
| relevant factor exacerbation | #3 |
| technique uncontrollable | #3 |
| vkc cell | #3 |
| higher muc1 eyes | #3 |
| dfna diclofenac epithelium | #3 |
| 3 sjögrens syndrome | #3 |
| ssdry | #3 |
| icecold eye mask | #3 |
| papillary regrowth | #3 |
| insensible administration insensible | #3 |
| vivo corneal akc | #3 |
| underwent staining | #3 |
| akc comorbidities | #3 |
| treatment oral pilocarpine | #3 |
| eye cooling | #3 |
| uncontrollable glaucoma | #3 |
| alterations tear | #3 |
| conjunctival corneal | #3 |
| histamine conjunctival cells | #3 |
| histamine superficial cells | #3 |
| phenomena tacrolimus | #3 |
| nuclei vkc | #3 |
| tear periostin patients | #3 |
| akc dyes humans | #3 |
| cells brush cytology | #3 |
| fibers lnfs | #3 |
| eyes akc | #3 |
| allergic postsurgical | #3 |
| healing dramatic healing | #3 |
| ulcer akc | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| sensitivity tear | #3 |
| existence par2 mrna | #3 |
| 5ac mrna | #3 |
| vkc levels | #3 |
| eye washing | #3 |
| dramatic healing | #3 |
| lamp device | #3 |
| autumnal pollen | #3 |
| insufficient tear supply | #3 |
| 13 eyes 69 | #3 |
| tear periostin comorbidities | #3 |
| muc1 brush cytology | #3 |
| macroerosions | #3 |
| 005 mmc | #3 |
| protein conjunctival fibroblasts | #3 |
| glaucoma amniotic | #3 |
| production conjunctival | #3 |
| keratoconjunctivitis vkc | #3 |
| 111 177 | #3 |
| allerwatch | #3 |
| 5ac brush | #3 |
| efficacy bromfenac | #3 |
| ocular surface diabetes | #3 |
| antieaigg | #3 |
| conjunctiva conjunctivitis | #3 |
| patients tmh measurements | #3 |
| keratoconjunctivitis leupeptins | #3 |
| evaluate tear | #3 |
| sligkv examined | #3 |
| conjunctival disease | #3 |
| pilocarpine visante | #3 |
| july pm25 | #3 |
| pretreatment docosahexaenoic acid | #3 |
| eosinophils corneal | #3 |
| postsurgical conjunctivitis | #3 |
| improvement squamous metaplasia | #3 |
| eyes control subjects | #3 |
| par2 cultured | #3 |
| akc confocal | #3 |
| 5 eyes akc | #3 |
| nbs normal eyes | #3 |
| techniques tears | #3 |
| pollen august | #3 |
| conjunctivitis allergic | #3 |
| dfna eye dfna | #3 |
| vkc exacerbation | #3 |
| papillary resection | #3 |
| ulcers plaques | #3 |
| corneal epithelial structure | #3 |
| increased comfort | #3 |
| titers ade | #3 |
| cornea atopic | #3 |
| eyes vkc | #3 |
| conjunctivitis negative | #3 |
| cell metry | #3 |
| oct graticule | #3 |
| epithelium adverse | #3 |
| akc higher muc1 | #3 |
| akc serum periostin | #3 |
| diclofenac epithelium | #3 |
| solutions prospective | #3 |
| akc rose bengal | #3 |
| samples correlate | #3 |
| akc alterations | #3 |
| 005 ophthalmic solution | #3 |
| prospectively diclofenac | #3 |
| vkc 5 eyes | #3 |
| il1beta th2 | #3 |
| healing allergic | #3 |
| study cutometer | #3 |
| permeability postoperatively | #3 |
| histamine specimens | #3 |
| epithelial disease eyes | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| 061 028 degree | #4 |
| highrisk glaucoma patients | #4 |
| clinical conjunctival | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| rsv allergic reaction | #4 |
| allergic conjunctivitis rsv | #4 |
| allergic conjunctival diseases | #4 |
| allergies blinding | #4 |
| treatment vmr values | #4 |
| samples histocytological | #4 |
| solutions piperidines | #4 |
| epithelial muc16 | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| acds conventional | #4 |
| erosion shield | #4 |
| staining muc16 | #4 |
| controls brush cytology | #4 |
| controls interferometry | #4 |
| allergic epidemiologic studies | #4 |
| wilcoxon signed test | #4 |
| allergic patients elisa | #4 |
| aged rose | #4 |
| inflammation akc | #4 |
| papillae normal | #4 |
| hypersensitivity mucin | #4 |
| interferometry controls | #4 |
| ige conjunctival | #4 |
| allergic cytological | #4 |
| adolescent betamethasone | #4 |
| assay pgd2 | #4 |
| oedema papillary | #4 |
| 34 15 seconds | #4 |
| vkc messenger reverse | #4 |
| eyes video | #4 |
| akc crth2 | #4 |
| ded 1 | #4 |
| greater 3 grade | #4 |
| controls interferometry grade | #4 |
| completely severe | #4 |
| akc chemotaxis | #4 |
| muc16 goblet | #4 |
| akc crth2 expression | #4 |
| conventional portable | #4 |
| include ocular | #4 |
| crth2 akc | #4 |
| cell muc5ac | #4 |
| giemsas staining | #4 |
| ocular allergic disease | #4 |
| rose bengal scores | #4 |
| tryptase dose | #4 |
| hydrochloride ophthalmic | #4 |
| scores conjunctival | #4 |
| underwent corneal | #4 |
| ophthalmologists eye drops | #4 |
| 020 013 | #4 |
| epithelial cells rsv | #4 |
| histamine h1 antagonist | #4 |
| tears pathogenesis | #4 |
| trantas | #4 |
| performed tears | #4 |
| sterilized asian dust | #4 |
| diseases portable | #4 |
| pgd2dependent migration | #4 |
| samples allergic | #4 |
| p0001 brush | #4 |
| eyes corneal ulcers | #4 |
| acds ophthalmologists | #4 |
| special brush | #4 |
| fva treatment | #4 |
| tear function test | #4 |
| muc5ac mrna expression | #4 |
| samples immunocytochemical | #4 |
| allergic conjunctival | #4 |
| greater concentrations tears | #4 |
| subjects muc5ac | #4 |
| akc healthy | #4 |
| conjunctivitis levels | #4 |
| cytometry mild | #4 |
| 10 seconds temperature | #4 |
| blinding purpose | #4 |
| tablets tears | #4 |
| ulcers atopic | #4 |
| allergic conjunctival disease | #4 |
| insignificant epithelial | #4 |
| pathogenesis noninfectious | #4 |
| male ophthalmic | #4 |
| deqs scores | #4 |
| infected conjunctival | #4 |
| keratoconjunctivitis lacrimal | #4 |
| fibroblasts primary sources | #4 |
| microscope evaluating | #4 |
| corneal safety | #4 |
| patients epithelial disease | #4 |
| corneal temperature blink | #4 |
| levocabastine ophthalmic | #4 |
| corneal ulcers muc5ac | #4 |
| tacrolimus conclusions | #4 |
| patient eyes fluorescein | #4 |
| 3004 respondents | #4 |
| thinoptx lens | #4 |
| folliculosis | #4 |
| drop artificial tears | #4 |
| akc pgd2dependent migration | #4 |
| mucin mucins tears | #4 |
| surface muc5ac | #4 |
| conjunctival papillary | #4 |
| corneal sensitivity measurements | #4 |
| primary sources chemokines | #4 |
| akc sac | #4 |
| stimulation chemokine expression | #4 |
| crth2 peripheral | #4 |
| eye sjögrens syndrome | #4 |
| keratoconjunctivitis purpose | #4 |
| cultured conjunctival | #4 |
| treatment vmr | #4 |
| bromfenac ophthalmic | #4 |
| tear function patients | #4 |
| cytometry mild cases | #4 |
| patients severe vkc | #4 |
| pgd2 normal volunteers | #4 |
| compared vkc | #4 |
| alterations atopic | #4 |
| interleukin2 tears | #4 |
| dust wheal | #4 |
| topical 01 tacrolimus | #4 |
| epithelial muc | #4 |
| severe ocular allergies | #4 |
| epithelial pge2 production | #4 |
| cytology goblet | #4 |
| insignificant epithelial disease | #4 |
| weeks vital | #4 |
| ophthalmologists evaluated | #4 |
| lower tear function | #4 |
| epinastine hydrochloride | #4 |
| chemotaxis conjunctiva | #4 |
| chemokine genes fibroblasts | #4 |
| conjunctivitis methods | #4 |
| recordable slit | #4 |
| defensins greater | #4 |
| conjunctiva differences | #4 |
| interferometry 2 | #4 |
| studied corneal | #4 |
| exponential equation inclination | #4 |
| cells lnfs | #4 |
| ulcers mucin | #4 |
| sensitization asian dust | #4 |
| portable slit | #4 |
| levocabastine h1 | #4 |
| disease akc | #4 |
| months papillary | #4 |
| rejection limbal | #4 |
| noninfectious necrotizing | #4 |
| lesions regrowth | #4 |
| 2 4 alterations | #4 |
| topical oral steroids | #4 |
| implantation thinoptx | #4 |
| interferometry lipids | #4 |
| par2 mrna protein | #4 |
| conjunctiva density | #4 |
| 2010 allergic | #4 |
| ulcers control subjects | #4 |
| eye operation | #4 |
| thermometer 20 | #4 |
| vkc normal controls | #4 |
| sac grade | #4 |
| conjunctival proliferative | #4 |
| persistent 6 | #4 |
| corneal temperature eye | #4 |
| mucins tears mucin | #4 |
| metaregression analysis effects | #4 |
| pgd2dependent migration eosinophils | #4 |
| eosinophil toxic activity | #4 |
| simple resection | #4 |
| individuals pgd2 | #4 |
| specimens underwent | #4 |
| 33 chemokines | #4 |
| thinoptx acrysof | #4 |
| tomography tear | #4 |
| membrane patching | #4 |
| fungi epidemiologic studies | #4 |
| eotaxin1 rantes | #4 |
| ocular surface epithelial | #4 |
| papillae giant | #4 |
| eyes ulcers | #4 |
| july pollen | #4 |
| asian dust extract | #4 |
| cases sufficient examination | #4 |
| eyes sac | #4 |
| thinoptx intraocular | #4 |
| vmr 3 months | #4 |
| staining muc | #4 |
| bromfenac eye drops | #4 |
| genes conjunctival | #4 |
| akc immunologic receptors | #4 |
| eye wash solution | #4 |
| conjunctivitis ige | #4 |
| corneal sensitivity measurement | #4 |
| tears patients | #4 |
| 18 akc patients | #4 |
| atopic ocular | #4 |
| moisture checker | #4 |
| eyes akc patients | #4 |
| eyes epithelial disease | #4 |
| 0001 brush | #4 |
| akcaffected patients | #4 |
| dscg day | #4 |
| muc16 muc5ac alterations | #4 |
| interferometry grade | #4 |
| staining ocular | #4 |
| conjunctivitis vkc | #4 |
| formation conjunctivitis | #4 |
| atopic dermatitis remission | #4 |
| thermography anterior | #4 |
| il4 tears | #4 |
| sac control eyes | #4 |
| atopic ocular allergies | #4 |
| metaplasia reduction | #4 |
| muc5ac alterations | #4 |
| rsv conjunctiva | #4 |
| severe vkc patients | #4 |
| akc rtpcr | #4 |
| allergic fibroblasts | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| surface conjunctival | #4 |
| p0001 impression | #4 |
| akc healthy individuals | #4 |
| sio2 20 | #4 |
| vkc 4 | #4 |
| implantation rollable | #4 |
| tnfalpha30ng | #4 |
| tears 10 patients | #4 |
| muc5ac brush | #4 |
| photophobia diagnosis | #4 |
| bengal sensation | #4 |
| steroids fluorometholone | #4 |
| sensation tears | #4 |
| goblet cell muc5ac | #4 |
| muc1 2 | #4 |
| cornea grading scale | #4 |
| eyes thinoptx | #4 |
| tear temperature | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| 4 chemokines stimulation | #4 |
| level conjunctiva | #4 |
| corneal ulcers eyes | #4 |
| mucins 1 | #4 |
| defensins conjunctivitis | #4 |
| rsv conjunctival epithelium | #4 |
| lower tear clearance | #4 |
| atopic vernal | #4 |
| vkc male receptors | #4 |
| immunologic receptors akc | #4 |
| muc5ac brush cytology | #4 |
| patients topical cyclosporine | #4 |
| acuity akc | #4 |
| untreated asian dust | #4 |
| limbal grafts | #4 |
| correlation outpatient | #4 |
| patient atopic keratoconjunctivitis | #4 |
| epithelial disease patients | #4 |
| ari ono2235 | #4 |
| steroids iop | #4 |
| diameter allergen | #4 |
| sterilized asian | #4 |
| eyes insignificant | #4 |
| pcr epithelial | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| excision papillary | #4 |
| grade dry eye | #4 |
| placebo ophthalmic | #4 |
| proteinchip array elisa | #4 |
| temperature corneal | #4 |
| healthy individuals rtpcr | #4 |
| eosinophils receptor crth2 | #4 |
| thinoptx | #4 |
| eye warmer treatment | #5 |
| severe conjunctivitis | #5 |
| situ nickend regulation | #5 |
| supernatants conjunctival | #5 |
| damage impression | #5 |
| 310±165 years | #5 |
| cornea explain | #5 |
| crth2 eosinophils | #5 |
| warmer improved | #5 |
| allergic female | #5 |
| akc ecp | #5 |
| accompanying allergic | #5 |
| vkc atopic | #5 |
| conjunctiva dermatitis | #5 |
| females akc | #5 |
| intraoperative mitomycin excision | #5 |
| meniscus punctal | #5 |
| schiff immunohistochemical | #5 |
| 005 schirmer1 | #5 |
| anterior fluorometry | #5 |
| hel cytokines | #5 |
| allergic keratopathy | #5 |
| alterations ocular | #5 |
| crth2 prostaglandin receptors | #5 |
| histamine superficial | #5 |
| study epinastine | #5 |
| scans akc | #5 |
| prostaglandin chemotaxis | #5 |
| oct lower | #5 |
| stained conjunctival | #5 |
| controls ebv | #5 |
| 20 sio2 | #5 |
| schirmer1 test groups | #5 |
| warmer applied | #5 |
| disease conjunctivitis | #5 |
| pm25 outpatient | #5 |
| 0001 strip | #5 |
| diclofenac eye | #5 |
| staining administration | #5 |
| lipid oxidation hel | #5 |
| trantas dots | #5 |
| eosinophils immunologic receptors | #5 |
| adolescent conjunctivitis | #5 |
| equipment dry | #5 |
| treatment epinastine | #5 |
| conjunctival confocal microscopy | #5 |
| impression cytology samples | #5 |
| human conjunctival fibroblasts | #5 |
| antifungal mcfg | #5 |
| cases tests | #5 |
| 7 conjunctival | #5 |
| treatment tacrolimus ointment | #5 |
| punctal occlusion oct | #5 |
| pgd2 normal | #5 |
| conjunctivitis prostaglandin | #5 |
| akc hel | #5 |
| conjunctiva mmc | #5 |
| ulcer dermatitis | #5 |
| impression brush | #5 |
| visits july | #5 |
| severity akc | #5 |
| regulation allergic cornea | #5 |
| tears received | #5 |
| akc disease | #5 |
| lower atopic | #5 |
| akc normal subjects | #5 |
| month tear | #5 |
| bengal suture | #5 |
| hel ihc | #5 |
| akc laser | #5 |
| signs akc | #5 |
| stainings tear | #5 |
| labeling surface akc | #5 |
| dryeye symptoms | #5 |
| damaged eosinophil | #5 |
| akc patients study | #5 |
| wilcoxonmatched pair test | #5 |
| allergic cyclosporine | #5 |
| 376±56 years | #5 |
| tnfα costimulation | #5 |
| keratoconjunctivitis giant | #5 |
| eye warmer | #5 |
| disposable eyelidwarming device | #5 |
| layer mgd | #5 |
| corneal involvement | #5 |
| solution olopatadine | #5 |
| eye circulating | #5 |
| severe stevensjohnson syndrome | #5 |
| postsurgical inflammation | #5 |
| mcfg eye | #5 |
| stimulated conjunctival | #5 |
| treatment dryeye symptoms | #5 |
| fibroblasts fibroblast damage | #5 |
| ocular anesthesia | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| mitomycin excision | #5 |
| il4 histamine | #5 |
| hel akc | #5 |
| array chemotaxis | #5 |
| younger age effects | #5 |
| conjunctival allergen | #5 |
| allergic conjunctivitis patients | #5 |
| eosinophils activated fibroblasts | #5 |
| controls inflammatory cells | #5 |
| akc acinar | #5 |
| inflammation mitomycin | #5 |
| conventional steroid treatment | #5 |
| keratoconjunctivitis objective | #5 |
| age 9 ± | #5 |
| ocular surface disorder | #5 |
| visits august | #5 |
| inflammatory cells hel | #5 |
| ihc conjunctival inflammation | #5 |
| local tear | #5 |
| temperature blink | #5 |
| staining muc5ac | #5 |
| hne ihc | #5 |
| fibroblasts eosinophil adherence | #5 |
| 17 mgd patients | #5 |
| eosinophil adherence fibroblasts | #5 |
| allergic drug therapy | #5 |
| upper palpebral | #5 |
| 3 cases followup | #5 |
| conjunctival inflammatory status | #5 |
| conjunctivitis pollen | #5 |
| ophthalmic suspension | #5 |
| treatment shield | #5 |
| measurements strip | #5 |
| simple papillary | #5 |
| eosinophil adhesion fibroblasts | #5 |
| vkc iop | #5 |
| ulcers controls | #5 |
| injection conjunctival | #5 |
| thinoptx iol | #5 |
| topical cyclosporine therapy | #5 |
| months amniotic | #5 |
| status confocal | #5 |
| dryeye symptoms treatment | #5 |
| pretreatment dha | #5 |
| bromobenzenes cornea | #5 |
| case corneal ulcer | #5 |
| ophthalmic test | #5 |
| lesion corneal | #5 |
| 20 akc patients | #5 |
| 5 females akc | #5 |
| solutions pollen | #5 |
| vcam1 fibroblasts | #5 |
| accompanied varying | #5 |
| thiazolidines administration | #5 |
| 01 mcfg | #5 |
| cornea cytodiagnosis | #5 |
| alpha allergic | #5 |
| conjunctival lipid | #5 |
| adhered corneal | #5 |
| worse akc | #5 |
| samples akc | #5 |
| corneal fibroblasts icam1 | #5 |
| ocular allergic | #5 |
| asthenopia dry | #5 |
| cytokinestimulation | #5 |
| 15 minutes dose | #5 |
| scores expressibility | #5 |
| disposable eyelid | #5 |
| 329±57 years | #5 |
| cells vkc | #5 |
| endophthalmitis eosinophils | #5 |
| diseases required | #5 |
| anterior scleritis patients | #5 |
| hyperemia imidazoles | #6 |
| dfna | #6 |
| ocular surface findings | #6 |
| obstructive mgd patients | #6 |
| upper tarsal conjunctiva | #6 |
| tears acinar | #6 |
| challenge cac | #6 |
| elevation refractory | #6 |
| tear meniscus patients | #6 |
| concomitant eye | #6 |
| fva landolt | #6 |
| tear ecp | #6 |
| findings dry eye | #6 |
| density conjunctival | #6 |
| sac vkc | #6 |
| specimens akc | #6 |
| bengal vital stainings | #6 |
| antiallergic eye | #6 |
| induced tear | #6 |
| patients visante | #6 |
| conjunctival confocal | #6 |
| betamethasone oral | #6 |
| agents interferometry | #6 |
| sde ade | #6 |
| cgvhd improvements | #6 |
| patients seldi | #6 |
| noninvasive suction device | #6 |
| topical cys | #6 |
| eyes atopic | #6 |
| allergic conjunctivitis cac | #6 |
| corneal fibroblasts pathogenesis | #6 |
| tbut vital | #6 |
| eosinophils crth2 | #6 |
| pcr muc5ac | #6 |
| treatment postoperative inflammation | #6 |
| regulation benzamidines | #6 |
| ocular fatigue | #6 |
| itching conjunctival | #6 |
| coated elf | #6 |
| tear eosinophil | #6 |
| severe vkc | #6 |
| severe vernal | #6 |
| signs scored | #6 |
| hyperemia swelling | #6 |
| topical levocabastine | #6 |
| inflammatory cell densities | #6 |
| twicedaily instillation | #6 |
| female fluorometholone | #6 |
| edema severity | #6 |
| defect penetrating | #6 |
| corneal damage | #6 |
| elasticity cutometer | #6 |
| evaporation vital | #6 |
| july correlation | #6 |
| papillae mucous | #6 |
| tryptase proliferation | #6 |
| tranilast inhibition | #6 |
| conjunctival diseases | #6 |
| severe stevens | #6 |
| eosinophil recruiting chemokines | #6 |
| allergens cedrus | #6 |
| testing tear | #6 |
| ecp markers | #6 |
| dressings female | #6 |
| atopic eyelids | #6 |
| differences tear | #6 |
| functions topical | #6 |
| treatment tacrolimus | #6 |
| intolerable irritation | #6 |
| tears xerophthalmia | #6 |
| severe ocular inflammation | #6 |
| controlling eyelid | #6 |
| topical cys treatment | #6 |
| rose bengal dyes | #6 |
| extract sterilized | #6 |
| ade sde | #6 |
| dust asian | #6 |
| dermatitis scored | #6 |
| akc refractory | #6 |
| examinations tear | #6 |
| conjunctivitis sac | #6 |
| cyclosporine 01 | #6 |
| defect ped | #6 |
| samples underwent | #6 |
| chloride eye | #6 |
| akc vernal keratoconjunctivitis | #6 |
| grading tear | #6 |
| 20 pbs | #6 |
| schirmer1 test values | #6 |
| oxidation hel | #6 |
| fibroblasts conjunctival | #6 |
| symptoms vkc | #6 |
| levels air pollutants | #6 |
| fluorometholone follow | #6 |
| tear stability values | #6 |
| syndrome tablets | #6 |
| solution commercial | #6 |
| ointment blood | #6 |
| tacrolimus chronic | #6 |
| remodeling vkc | #6 |
| il4 il2r | #6 |
| levocabastine effective | #6 |
| cys ocular | #6 |
| 4 9 genes | #6 |
| rate tbut | #6 |
| conjunctival brush cytology | #6 |
| scores goblet | #6 |
| strip meniscometry scores | #6 |
| allergic diathesis | #6 |
| corneal temperature | #6 |
| 4 muc | #6 |
| eye evaluated | #6 |
| pathogenesis ocular | #6 |
| rtpcr epithelial cells | #6 |
| diseases periostin | #6 |
| instability conjunctival | #6 |
| concentrations conjunctival | #7 |
| prostaglandin atopic | #7 |
| ulceration healthy | #7 |
| conjunctivitis risk | #7 |
| accommodating intraocular lens | #7 |
| conjunctival inflammatory | #7 |
| 0001 impression | #7 |
| crth2 normal | #7 |
| conjunctiva brush | #7 |
| sensitization asian | #7 |
| evaluation eyelid | #7 |
| solution bf | #7 |
| status atopic | #7 |
| rose bengal fluorescein | #7 |
| tear supply | #7 |
| papillae formation | #7 |
| vkc gpc | #7 |
| surgery cooling | #7 |
| pgd2 dependent | #7 |
| normal blinking | #7 |
| mmc observed | #7 |
| sources chemokines | #7 |
| superiority placebo | #7 |
| ulcer corneal | #7 |
| corneal lesion | #7 |
| cytology differ | #7 |
| meniscometry testing | #7 |
| key prostaglandin | #7 |
| gpc vkc | #7 |
| pathogenesis subsequent | #7 |
| tears alpha | #7 |
| amniotic membrane patching | #7 |
| procedures radioimmunoassay | #7 |
| inhibitor ono2235 | #7 |
| allergic eyelid | #7 |
| steroidal benzophenones | #7 |
| thought pathogenesis | #7 |
| conjunctival complications | #7 |
| revealed eosinophils | #7 |
| improvements symptom scores | #7 |
| conjunctivitis dry | #7 |
| patients comfort level | #7 |
| western blotting nfκb | #7 |
| increases proliferative | #7 |
| mucins periodic | #7 |
| tacrolimustreated eyes | #7 |
| tmh measurements | #7 |
| nerves tear | #7 |
| mmc 005 | #7 |
| tears th2 | #7 |
| conclusion mmc | #7 |
| eyes ophthalmologists | #7 |
| injection oedema | #7 |
| ulcers revealed | #7 |
| hrtii rcm | #7 |
| hyperemia adverse | #7 |
| tacrolimus topical steroids | #7 |
| eyelid surface | #7 |
| neutrophils corneal | #7 |
| severe persistent cases | #7 |
| allergic dna | #7 |
| alpha tears | #7 |
| eczema frequently | #7 |
| 10 clinical signs | #7 |
| ocular inflammatory disorder | #7 |
| age 325 years | #7 |
| development allergic conjunctivitis | #7 |
| pge2 cox2 levels | #7 |
| collected brush | #7 |
| administration fluorescein | #7 |
| conjunctival brush | #7 |
| examination tear | #7 |
| 4 tear | #7 |
| mucins tears | #7 |
| silicone plugs | #7 |
| suspension 01 | #7 |
| attendance allergic | #7 |
| chemotaxis eosinophils | #7 |
| nonparametric tears | #7 |
| sensation symptom | #7 |
| cases preventing | #7 |
| incidence meibomian | #7 |
| necrotizing anterior | #7 |
| adult blepharitis | #7 |
| corneal ulcer | #8 |
| pathogenesis test | #8 |
| transient burning sensation | #8 |
| occlusion lacrimal | #8 |
| patients corneal | #8 |
| blink patients | #8 |
| age 170 ± | #8 |
| pollen odds | #8 |
| conjunctival findings | #8 |
| chemotaxis pgd2 | #8 |
| rollable intraocular | #8 |
| akc subjects | #8 |
| graticule scale | #8 |
| fva measurements | #8 |
| meniscometry tear | #8 |
| tnfalpha eosinophils | #8 |
| patients vkc | #8 |
| 4 chemokines | #8 |
| noninfectious corneal | #8 |
| induced intraocular | #8 |
| il4 enzyme | #8 |
| corneal epithelial lesions | #8 |
| meniscometry scores | #8 |
| ulcers detected | #8 |
| superficial cells groups | #8 |
| controls brush | #8 |
| definite dry eye | #8 |
| betamethasone calcineurin | #8 |
| underwent tear | #8 |
| blinking body | #8 |
| asia cats | #8 |
| blinking desiccation | #8 |
| microscopy conjunctival | #8 |
| allergic dibenzazepines | #8 |
| surface teros | #8 |
| techniques keratoconjunctivitis | #8 |
| scores teros | #8 |
| controls seldi | #8 |
| correlation vital | #8 |
| sac akc | #8 |
| ihc hel | #8 |
| 006 degree | #8 |
| trabeculectomy amniotic | #8 |
| staining hel | #8 |
| alterations cornea | #8 |
| stained hel | #8 |
| classified allergic | #8 |
| alterations allergic | #8 |
| stainings schirmer | #8 |
| radiation thermography | #8 |
| palpebral bulbar | #8 |
| teros values | #8 |
| oedema scores | #8 |
| eye redness | #8 |
| conjunctival sensation | #8 |
| expressions thought | #8 |
| values slit | #8 |
| keratocytes cytokines | #8 |
| mitomycin post | #8 |
| ccl5 conjunctiva | #8 |
| teros | #8 |
| diameter acinar | #8 |
| itching hyperemia | #8 |
| brush cytology | #8 |
| flare counts | #8 |
| infrared radiation thermometry | #8 |
| corneal scores | #8 |
| par2 mast cells | #8 |
| limbalbased conjunctival flap | #8 |
| fluorescein rose bengal | #8 |
| corneal fibroblasts tnfalpha | #8 |
| akc patients controls | #8 |
| conjunctivitis eyes | #8 |
| hoc analysis study | #8 |
| conjunctivitis cases | #9 |
| cobblestone papillae | #9 |
| symptoms allergic conjunctivitis | #9 |
| elisa tears | #9 |
| sensitivity conjunctival | #9 |
| cases conjunctivitis | #9 |
| sufficient examination | #9 |
| clinical ocular findings | #9 |
| pilocarpine tablets | #9 |
| reductase cataract | #9 |
| pollution conjunctivitis | #9 |
| hel 4 | #9 |
| smart eye | #9 |
| prevalence weather | #9 |
| prevalence vkc | #9 |
| untreated asian | #9 |
| blood level tacrolimus | #9 |
| mmc recurrence | #9 |
| 0001 schirmer | #9 |
| tacrolimus treating | #9 |
| wash solution | #9 |
| tear level | #9 |
| sio2 pbs | #9 |
| fatigue dry | #9 |
| ono2235 | #9 |
| crth2 expression eosinophils | #9 |
| foreign body sensation | #9 |
| specular microscopic evaluation | #9 |
| operatedon eye | #9 |
| observed obstructive | #9 |
| superior limbic | #9 |
| acid goblet | #9 |
| diseases conjunctivitis | #9 |
| fluorescein rose | #9 |
| pathogen allergic | #9 |
| patients tacrolimus treatment | #9 |
| vital staining scores | #9 |
| level pollutants | #9 |
| prospective study tacrolimus | #9 |
| severity corneal | #9 |
| vital stainings | #9 |
| subjective ocular | #9 |
| eye normal subjects | #9 |
| shield ulcers | #9 |
| injection edema | #9 |
| hyperemia iop | #9 |
| differ allergic | #9 |
| inflammation steroidal | #9 |
| glaucoma younger age | #9 |
| concentration tears | #9 |
| supply superior | #9 |
| design eyelid | #9 |
| diagnosis conjunctivitis | #9 |
| measurements vital | #9 |
| implantation 1cu | #9 |
| pretreatment docosahexaenoic | #9 |
| genes cxc | #9 |
| received preserved | #9 |
| histocytological study | #9 |
| tacrolimus 95 | #9 |
| stress staining | #9 |
| tears thermography | #9 |
| conjunctival fibroblast | #9 |
| eye grade | #9 |
| cys eye | #9 |
| tnfalpha fibroblasts | #9 |
| sensitivity confocal | #9 |
| excision intraoperative | #9 |
| levels tears | #10 |
| central graft | #10 |
| allergic ocular | #10 |
| aged conjunctivitis | #10 |
| bengal stainings | #10 |
| substance tears | #10 |
| total tear ige | #10 |
| complain | #10 |
| humans mucin | #10 |
| conjunctival edema | #10 |
| layer alterations | #10 |
| iop hyperemia | #10 |
| measuring tear | #10 |
| assessed conjunctival | #10 |
| resection regrowth | #10 |
| cornea eosinophils | #10 |
| conjunctivitis japan | #10 |
| muc5ac muc16 | #10 |
| nonallergic conjunctivitis | #10 |
| muc16 muc5ac | #10 |
| drugs conjunctival | #10 |
| allergic bronchitis | #10 |
| subbasal stromal | #10 |
| allergic conjunctivitis spring | #10 |
| underwent slit | #10 |
| shield ulcer | #10 |
| cytometry il4 | #10 |
| evaluation atopic | #10 |
| functions dry | #10 |
| incubated il4 | #10 |
| conjunctivitis histamine | #10 |
| meibomian gland obstruction | #10 |
| eye surface | #10 |
| lower tmh | #10 |
| humans conjunctival | #10 |
| improvement tear | #10 |
| measurement strip | #10 |
| insufficient local | #10 |
| eye infrared | #10 |
| ophthalmic adolescent | #10 |
| staining brush | #10 |
| chemokines cxc chemokines | #10 |
| sensation ocular | #10 |
| conjunctivitis atopic | #10 |
| tears 10 | #10 |
| par2 mast | #10 |
| leupeptin benzamidine | #10 |
| topical cyclosporine patients | #10 |
| vmr values | #10 |
| laminin actins | #10 |
| conjunctivitis spring | #10 |
| proliferation conjunctival | #10 |
| treatment vkc | #10 |
| compared eyes | #10 |
| staining oral | #10 |
| scale tear | #10 |
| icam1 tnfalpha | #10 |
| punctal occlusion | #10 |
| status conjunctival | #10 |
| tear cytology | #10 |
| produced conjunctival | #10 |
| crth2 chemotaxis | #10 |
| eye clinically | #10 |
| patients ulcers | #10 |
| diagnosis dry eye | #10 |
| lacrimal puncta | #10 |
| visante optical | #10 |
| association outpatient | #11 |
| vkc | #11 |
| methods conjunctival | #11 |
| vcam1 tnfalpha | #11 |
| count conjunctivitis | #11 |
| 1 month reduction | #11 |
| tears conjunctival | #11 |
| keratitis observed | #11 |
| amniotic membrane patch | #11 |
| cooling operation | #11 |
| smart eye camera | #11 |
| initiation tacrolimus | #11 |
| antivcaigg | #11 |
| elicited statistically | #11 |
| common conjunctival | #11 |
| test tear | #11 |
| genes corneal | #11 |
| elasticity treatment | #11 |
| levocabastine hydrochloride | #11 |
| prevalence dry eye | #11 |
| lamp microscope | #11 |
| diagnosis allergic | #11 |
| landolt visual | #11 |
| palpebral bulbar conjunctiva | #11 |
| sensation staining | #11 |
| surgery 13 eyes | #11 |
| therapy conjunctivitis | #11 |
| schirmer1 test | #11 |
| coherence dry | #11 |
| fibroblasts pathogenesis | #11 |
| elisa il4 | #11 |
| higher muc1 | #11 |
| hel hne | #11 |
| vkc adolescent | #11 |
| weeks papillary | #11 |
| preserved artificial | #11 |
| patient atopic | #11 |
| ophthalmic solution | #11 |
| disease edition | #11 |
| vkc normal | #11 |
| sensation tear | #11 |
| vernal | #11 |
| matched dry | #11 |
| cytometry oligonucleotide | #11 |
| purpose metaplasia | #11 |
| interleukin4 male | #11 |
| function ocular | #11 |
| anesthesia strabismus | #11 |
| drop artificial | #11 |
| vmr fva | #11 |
| eosinophils prostaglandin | #11 |
| extracts pollens | #12 |
| mmhg elevation | #12 |
| fva visual | #12 |
| 002 ophthalmic | #12 |
| density acinar | #12 |
| biomarker allergic | #12 |
| severe binocular | #12 |
| 001 specimens | #12 |
| fva vmr | #12 |
| eye diagnosed | #12 |
| levocabastine patients | #12 |
| immunologic rejection | #12 |
| 1cu accommodating | #12 |
| corneal shield | #12 |
| 1821 subjects | #12 |
| density muc5ac | #12 |
| fluorescein scores | #12 |
| ulcers squamous | #12 |
| leupeptins mast | #12 |
| surface diabetic | #12 |
| keratoconjunctivitis patients | #12 |
| appearance atopic | #12 |
| iop younger | #12 |
| tears conjunctivitis | #12 |
| drugs pge2 | #12 |
| conjunctival injection | #12 |
| supratarsal injection | #12 |
| projects tears | #12 |
| iop glucocorticoids humans | #12 |
| receptor crth2 | #12 |
| expression 8 genes | #12 |
| radiography tears | #12 |
| controls antibody titers | #12 |
| damage height | #12 |
| cornea density | #12 |
| highspeed highresolution | #12 |
| lacrimal punctal | #12 |
| dermatitis tacrolimus | #12 |
| coated lactoferrin | #12 |
| specimens eyes | #12 |
| microscopy efficient | #12 |
| conventional slit | #12 |
| mgd controls | #12 |
| acids chemokine | #12 |
| findings conjunctival | #12 |
| corneal aesthesiometry | #12 |
| patients sac | #12 |
| ccl11 conjunctiva | #12 |
| pemirolast potassium | #12 |
| 1cu iol | #12 |
| keratoplasty glaucoma | #12 |
| selected severity | #12 |
| time fluorescein | #13 |
| papillary samples | #13 |
| symptoms conjunctival | #13 |
| glaucoma keratoplasty | #13 |
| japan keratoconjunctivitis | #13 |
| vmr measurements | #13 |
| protein conjunctival | #13 |
| syndrome reactivation | #13 |
| months healed | #13 |
| anterior segment photography | #13 |
| compared postsurgical | #13 |
| specimens levels | #13 |
| outcomes 01 | #13 |
| called giant | #13 |
| treatment allergic conjunctivitis | #13 |
| upper tarsal | #13 |
| scraped samples | #13 |
| week corneal | #13 |
| thirty eyes | #13 |
| conjunctival oedema | #13 |
| epithelial disease | #13 |
| keratocytes incubated | #13 |
| remodeling relevant | #13 |
| aged disposable | #13 |
| coherence viscosupplements | #13 |
| bengal fluorescein | #13 |
| blood levels tacrolimus | #13 |
| ulcers corneal | #13 |
| cell flare | #13 |
| interferometry tear | #13 |
| 5ac ophthalmic | #13 |
| corneal complications | #13 |
| inflammation tear | #13 |
| topical cyclosporine treatment | #13 |
| tear hel | #13 |
| temperature cataract | #13 |
| conclusions ocular | #13 |
| dry eye examination | #13 |
| fluorometholone fml | #13 |
| glaucoma younger | #13 |
| tear functions | #13 |
| objective signs | #13 |
| suspensions tacrolimus | #13 |
| schirmers test values | #13 |
| improvement vital | #13 |
| sd105 | #13 |
| stability vital | #13 |
| applied operation | #13 |
| chemokines stimulation | #13 |
| dry eye controls | #14 |
| solutions retrospective | #14 |
| conjunctival impression | #14 |
| proliferative lesion | #14 |
| flare count | #14 |
| cornea endophthalmitis | #14 |
| bf 01 | #14 |
| clinically allergic | #14 |
| 14 flare | #14 |
| secrete mediators | #14 |
| higher allergic | #14 |
| functions corneal | #14 |
| conjunctival allergen challenge | #14 |
| clinical corneal | #14 |
| blinking patients | #14 |
| conjunctivitis vernal | #14 |
| benzamidines blotting | #14 |
| epithelial muc5ac | #14 |
| visits allergic | #14 |
| mcfg treatment | #14 |
| fungi adolescent | #14 |
| conjunctivitis background | #14 |
| factors conjunctivitis | #14 |
| test rose | #14 |
| fluorometholone humans | #14 |
| eyes 002 | #14 |
| conjunctival muc5ac | #14 |
| radioimmunoassay tears | #14 |
| schirmer1 | #14 |
| pilocarpine effective | #14 |
| fibroblast damage | #14 |
| vehicle eye | #14 |
| occlusion dry | #14 |
| density tear | #14 |
| giant papillary | #15 |
| adherence fibroblasts | #15 |
| olopatadine 01 | #15 |
| vkc methods | #15 |
| analysis par2 | #15 |
| mucous discharge | #15 |
| tmh values | #15 |
| ocular surface mucins | #15 |
| diseases 2020 | #15 |
| receptor pgd2 | #15 |
| investigated corneal | #15 |
| ige ecp | #15 |
| occlusion oct | #15 |
| basal tear secretion | #15 |
| ocular acrylic | #15 |
| ulcer echinocandins | #15 |
| ophthalmology tokyo | #15 |
| complications height | #15 |
| effects benzalkonium | #15 |
| correlation tear | #15 |
| improvement corneal | #15 |
| examined existence | #15 |
| tranilast anti | #15 |
| rtpcr cytometry | #15 |
| agents blepharitis | #15 |
| patients vernal | #15 |
| expression realtime pcr | #15 |
| complications mmc | #15 |
| superior conjunctiva | #15 |
| corneal recurrence | #15 |
| irritation scores | #15 |
| surface vital | #15 |
| firstline drug | #15 |
| day bf | #15 |
| ocular itching | #15 |
| cytology brush | #15 |
| evaluation conjunctival | #15 |
| blepharitis conjunctivitis | #15 |
| bilateral conjunctivitis | #15 |
| occlusion rose | #15 |
| mmc female follow | #15 |
| improvement subjective symptoms | #15 |
| damaged fibroblasts | #15 |
| eye drop treatment | #15 |
| steroidal cornea | #15 |
| bromobenzenes child | #15 |
| topical 01 | #15 |
| monitoring tear | #15 |
| female goblet | #16 |
| hours visit | #16 |
| safety 01 | #16 |
| patients vernal keratoconjunctivitis | #16 |
| dust allergic | #16 |
| ige correlation | #16 |
| alpha ortho | #16 |
| odds ratio remission | #16 |
| ari administration | #16 |
| 2 conjunctival | #16 |
| lacrimation | #16 |
| ulcers positive | #16 |
| treatment eyelid | #16 |
| segment photography | #16 |
| total clinical scores | #16 |
| fungi odds | #16 |
| eosinophils receptor | #16 |
| temperature conjunctiva | #16 |
| objective ocular | #16 |
| controls papillary | #16 |
| assessment conjunctival | #16 |
| reduction goblet | #16 |
| measurements tear | #16 |
| initiation objective | #17 |
| staining muc1 | #17 |
| sclera trabeculectomy | #17 |
| fibroblasts damaged | #17 |
| analyzed 005 | #17 |
| meniscometry | #17 |
| 13 females age | #17 |
| evaluation inflammatory | #17 |
| increased goblet cells | #17 |
| muc16 mrna | #17 |
| eyes schirmer | #17 |
| corneal sensation | #17 |
| clearance corneal | #17 |
| ocular allergic inflammation | #17 |
| drops eyes | #17 |
| signs ded | #17 |
| ceramide gel | #17 |
| agents cedrus | #17 |
| inhibitor ari | #17 |
| wear soft | #17 |
| betamethasone induced | #17 |
| conjunctival samples | #17 |
| warmer treatment | #17 |
| strip meniscometry | #17 |
| 20 normal patients | #17 |
| fibroblasts mcp1 | #17 |
| age dry | #17 |
| expression eotaxin1 | #17 |
| inflammation blotting | #17 |
| male ophthalmic solutions | #18 |
| rantes response | #18 |
| cd45 inflammatory | #18 |
| complete staining | #18 |
| pollen fungi | #18 |
| cytology decrease | #18 |
| test tears | #18 |
| tear function | #18 |
| cytology corneal | #18 |
| intraoperative 002 | #18 |
| lower eyes | #18 |
| differentiation inflammatory cells | #18 |
| trabeculectomy glaucoma | #18 |
| inflammation lenses | #18 |
| correlation clinical signs | #18 |
| decrease ocular | #18 |
| technique glaucoma | #18 |
| concentrations corneal | #18 |
| evaluation tear | #18 |
| ocular surface status | #18 |
| tear evaporation rate | #18 |
| obstructive dysfunction | #18 |
| groups spt | #18 |
| types dry eye | #18 |
| induce corneal | #18 |
| associations level | #18 |
| tnfα inflammatory response | #18 |
| bengal sjogren | #18 |
| fibroblasts giant | #18 |
| ulcers compared | #18 |
| 30 ige | #18 |
| noncl wearers | #18 |
| ulceration subjects | #18 |
| conclusion ocular | #18 |
| dibenzazepines dibenzoxepins | #18 |
| studies rose | #18 |
| higher tears | #18 |
| temperature artificial | #19 |
| vernal keratoconjunctivitis | #19 |
| seldi analysis | #19 |
| aged cautery | #19 |
| evaluated infrared | #19 |
| mitomycin ophthalmologic | #19 |
| inflammatory cells patients | #19 |
| staining scores | #19 |
| conjunctivitis topical | #19 |
| outpatient attendance | #19 |
| limbal allograft | #19 |
| ige tear | #19 |
| subjects underwent | #19 |
| measurements visante | #19 |
| eosinophils adhered | #19 |
| steroid female | #19 |
| human conjunctival | #19 |
| 1151 years | #19 |
| dha pretreatment | #19 |
| sodium 01 | #19 |
| operation applied | #19 |
| aged ophthalmic | #19 |
| prospective study eyes | #19 |
| beta1 il1beta | #19 |
| early efficacy | #19 |
| periostin biomarker | #19 |
| seldi proteinchip | #19 |
| 3 severe | #19 |
| effective tacrolimus | #19 |
| microscopy scans | #19 |
| sma performed | #19 |
| total signs | #19 |
| surface findings | #20 |
| conjunctivitis caused | #20 |
| plaques graded | #20 |
| corneal impression | #20 |
| treated 01 | #20 |
| proteins tears | #20 |
| allergic female humans | #20 |
| 022 pg | #20 |
| height tmh | #20 |
| mucin alterations | #20 |
| conjunctivitis primary | #20 |
| lower dry | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| ulcers cell | #20 |
| xerophthalmia adolescent | #20 |
| common ocular disorders | #20 |
| persistent epithelial defect | #20 |
| explain pathogenesis | #20 |
| pollen association | #20 |
| improvements ocular | #20 |
| patients strip | #20 |
| evaluate noninferiority | #20 |
| tears corneal | #20 |
| conclusion tacrolimus | #20 |
| echinocandins eye | #20 |
| summarized based | #20 |
| decreased conjunctival | #20 |
| symptoms allergic | #20 |
| bilateral agerelated cataract | #20 |
| cytology upper | #20 |
| crth2 expressed | #21 |
| ocular symptoms signs | #21 |
| patients concomitant treatment | #21 |
| levels hel | #21 |
| ige groups | #21 |
| eye control | #21 |
| fluorescence postoperative | #21 |
| radiation thermometer | #21 |
| cornea clinical | #21 |
| tears blood | #21 |
| induced topical | #21 |
| keratoconjunctivitis atopic | #21 |
| reduction topical | #21 |
| preventing corneal | #21 |
| microscopy patients | #21 |
| surface mucin | #21 |
| reaction tears | #21 |
| lipid oxidative | #21 |
| methane nonmethane hydrocarbons | #21 |
| adhesion fibroblast | #21 |
| eosinophils flow cytometry | #21 |
| conclusions topical | #21 |
| peripheral blood eosinophils | #21 |
| conjunctiva role | #21 |
| cultured conjunctiva | #21 |
| acuity assessment | #21 |
| symptoms include | #21 |
| eye smaller | #21 |
| patients cedar | #21 |
| film lipid | #21 |
| 01 tacrolimus | #22 |
| therapies allergic | #22 |
| muc5ac patients | #22 |
| epithelial lipid | #22 |
| serum periostin patients | #22 |
| fluorescein staining | #22 |
| fibroblasts anti | #22 |
| accommodation amplitude | #22 |
| eyes nerve | #22 |
| haze photorefractive | #22 |
| types ocular | #22 |
| correlation humidity | #22 |
| mgd adult | #22 |
| 005 topical | #22 |
| negative lower | #22 |
| flare anterior | #22 |
| disease atopic | #23 |
| patients topical steroids | #23 |
| corneal fluorescein | #23 |
| tests adenovirus | #23 |
| cooling applied | #23 |
| blood concentration tacrolimus | #23 |
| palpebral conjunctiva | #23 |
| 5 females | #23 |
| hrt confocal | #23 |
| solution compared | #23 |
| tear dynamics | #23 |
| 215 ± | #23 |
| il4 tnf | #23 |
| prospectively surgery | #23 |
| pge2 supernatants | #23 |
| score deqs | #23 |
| lamp examinations | #23 |
| labeling tears | #23 |
| diseases diclofenac | #23 |
| preschool conjunctivitis | #23 |
| 01 severe | #23 |
| layer interferometry | #23 |
| subjects squamous | #23 |
| function mucin | #23 |
| solution corneal | #23 |
| cell meter | #24 |
| interleukin4 oligonucleotide | #24 |
| ocular allergies | #24 |
| diseases web | #24 |
| warming device | #24 |
| samples conjunctival | #24 |
| tokyo dental | #24 |
| conjunctiva diabetes | #24 |
| 27yearold male patient | #24 |
| formation allergic | #24 |
| fungal corneal | #24 |
| histamine development | #24 |
| control tear | #24 |
| signs serum | #24 |
| dermatitis improved | #24 |
| bengal tears | #24 |
| vkc patients | #24 |
| local allergic reaction | #24 |
| edema drug | #24 |
| vital staining | #24 |
| tarsal conjunctiva | #24 |
| surface tear | #24 |
| layer tear | #24 |
| patients tacrolimus ointment | #24 |
| rtpcr rsv | #25 |
| vkc compared | #25 |
| atopic eosinophils humans | #25 |
| bengal scores | #25 |
| level tears | #25 |
| density squamous | #25 |
| vcam1 activated | #25 |
| 0001 dry | #25 |
| antigen conjunctiva | #25 |
| eyes epithelial | #25 |
| superficial cells | #25 |
| confocal prospective | #25 |
| rsv rtpcr | #25 |
| patients atopic diseases | #25 |
| dynamics tear | #25 |
| slitlamp examinations | #25 |
| corneal plaques | #25 |
| schedule eosinophil | #25 |
| protein rtpcr | #25 |
| steroid eye | #25 |
| staining goblet | #25 |
| damage adhesion | #26 |
| tbut tear | #26 |
| correlated corneal | #26 |
| specific ige positivity | #26 |
| conclusions improvement | #26 |
| wheal diameter | #26 |
| symptoms itching | #26 |
| acinar unit | #26 |
| rapid epithelialization | #26 |
| conjunctival inflammation | #26 |
| statistical decrease | #26 |
| dmem f12 medium | #26 |
| slit lamp examinations | #26 |
| smallincision cataract surgery | #26 |
| aureus detected | #26 |
| solutions corneal | #26 |
| adhered fibroblasts | #26 |
| subjects measuring | #26 |
| eyes topical | #26 |
| corneal ulcers | #26 |
| singletreatment groups | #26 |
| 005 immunoreactive | #26 |
| human α defensin | #26 |
| conjunctivitis | #26 |
| treatment meibomian | #26 |
| postkeratoplasty glaucoma | #26 |
| 100 nylon | #26 |
| level il4 | #26 |
| 01 topical | #26 |
| diseases ambient | #26 |
| lnfs | #26 |
| keratoconjunctivitis caused | #26 |
| actins collagen | #26 |
| 005 symptoms | #27 |
| 01 cyclosporine | #27 |
| conjunctival epithelial | #27 |
| antibodies brush | #27 |
| eosinophils fibroblasts | #27 |
| therapy conjunctiva | #27 |
| prescribed topical | #27 |
| oct prospective | #27 |
| factor exacerbation | #27 |
| child cytological | #27 |
| reaction sensation | #27 |
| associations prevalence | #27 |
| tear ocular | #27 |
| lymphocytes specimens | #27 |
| cytometry chemotaxis | #27 |
| alpha eosinophils | #27 |
| interleukin4 polymerase | #27 |
| epinastine | #27 |
| density subbasal | #27 |
| objective scores | #28 |
| papillae patients | #28 |
| chemotactic activity eosinophils | #28 |
| diseases proliferative | #28 |
| corneal ulceration | #28 |
| ophthalmic | #28 |
| severe ocular | #28 |
| il13 il1beta | #28 |
| stress atopic | #28 |
| prevalence allergic diseases | #28 |
| assessment tear | #28 |
| solutions ophthalmologic | #28 |
| conjunctiva dexamethasone | #28 |
| 2 iol | #28 |
| eosinophil adherence | #28 |
| provide relief | #28 |
| assay eosinophils | #28 |
| corneal vivo | #28 |
| 4 5ac | #28 |
| giant papillae | #28 |
| underwent immunohistochemical | #28 |
| conjunctival epithelial cells | #28 |
| flare cell | #29 |
| aged thermography | #29 |
| disease periostin | #29 |
| allergic regulation | #29 |
| performed morphometric | #29 |
| studies conjunctivitis | #29 |
| scores schirmer | #29 |
| inhibited tranilast | #29 |
| eye mask | #29 |
| corneal conjunctival | #29 |
| 5ac mucins | #29 |
| thermography adolescent | #29 |
| cys treatment | #29 |
| ketotifen fumarate | #29 |
| numbers inflammatory | #29 |
| sac compared | #29 |
| rosebengal | #29 |
| conjunctiva dose | #29 |
| ocular surface alterations | #30 |
| conjunctivitis humans | #30 |
| il2r serum | #30 |
| regrowth observed | #30 |
| tear serum | #30 |
| expressed crth2 | #30 |
| syndromes equipment | #30 |
| redness eye | #30 |
| tear ige | #30 |
| common adverse reaction | #30 |
| palpebral | #30 |
| mucins ophthalmic | #30 |
| conjunctivitis patients | #30 |
| minutes visit | #30 |
| effective artificial | #30 |
| symptoms accompanying | #30 |
| infection conjunctival | #30 |
| conjunctiva cells | #30 |
| fibroblasts protease | #30 |
| atopic diagnostic | #30 |
| specificity tears | #30 |
| dermatitis efficacy | #30 |
| inhibitors pollen | #30 |
| eye common | #30 |
| recruitment day | #30 |
| properties tears | #31 |
| meibomian gland secretion | #31 |
| disease summarized | #31 |
| atopic 10 | #31 |
| hel levels | #31 |
| combinations eosinophils | #31 |
| scores corneal | #31 |
| fibroblasts pcr | #31 |
| ige negative | #31 |
| levels july | #31 |
| worse observed | #31 |
| inflammation atopic | #31 |
| expressed eosinophils | #31 |
| dermatitis purpose | #31 |
| pathogenesis corneal | #31 |
| schirmer scores | #31 |
| neutrophils severity | #31 |
| vegf cultured | #31 |
| epithelial mucins | #31 |
| acuity fva | #31 |
| tear meniscus height | #32 |
| prostaglandin cell | #32 |
| western blotting effects | #32 |
| tgfbeta1 il1beta | #32 |
| signs improved | #32 |
| eye sjögren | #32 |
| substantial interrater agreement | #32 |
| schirmer test values | #32 |
| diagnosed dry | #32 |
| reduced steroid | #32 |
| expressibility | #32 |
| conjunctival cells | #32 |
| limbus cornea | #32 |
| sign scores | #32 |
| keratoconjunctivitis | #32 |
| deqs | #32 |
| analysis tears | #32 |
| seasonal young | #33 |
| conclusions confocal | #33 |
| count prostaglandin | #33 |
| haze score | #33 |
| edema correlated | #33 |
| 4 grades | #33 |
| visante | #33 |
| atopic skin disease | #33 |
| film break | #33 |
| ige histamine | #33 |
| levocabastine | #33 |
| immunoglobulin interferometry | #33 |
| numbers quantitative | #33 |
| allergic double | #33 |
| signs evaluated | #33 |
| muc 1 | #33 |
| iop induced | #33 |
| conjunctiva cytokines | #34 |
| il1beta tgfbeta1 | #34 |
| 10 objective | #34 |
| alpha fibroblasts | #34 |
| intraocular pressure surgery | #34 |
| bengal staining | #34 |
| proteinchip array | #34 |
| 01 effective | #34 |
| clinical signs patients | #34 |
| therapy histamine | #34 |
| treatment mgd | #34 |
| eyes corneal | #34 |
| fibroblasts purpose | #34 |
| fluorometholone glucocorticoids | #34 |
| eye 10 | #34 |
| hypertension tacrolimus | #35 |
| cyclosporine cys | #35 |
| virus capsid antigen | #35 |
| eye 20 | #35 |
| interrater reproducibility | #35 |
| 6 months conclusion | #35 |
| tear stability | #35 |
| objective symptoms | #35 |
| adult asthenopia | #35 |
| mucins prospective | #35 |
| severe allergic | #36 |
| efficacy groups | #36 |
| diseases eosinophil | #36 |
| humans keratoconjunctivitis | #36 |
| functional visual acuity | #36 |
| eyes acrysof | #36 |
| tear clearance | #36 |
| measured tear | #36 |
| anterior scleritis | #36 |
| differential dry | #36 |
| resection 005 | #36 |
| tear samples | #36 |
| schirmer 1 | #36 |
| vdt users | #36 |
| ocular surface inflammation | #36 |
| tacrolimus 12 | #37 |
| oct effective | #37 |
| 002 mmc | #37 |
| induced iop | #37 |
| conducted compliance | #37 |
| laser flarecell meter | #37 |
| eyelid skin | #37 |
| recurrence corneal | #37 |
| scleritis episcleritis | #37 |
| wellrecognized risk | #37 |
| delefilcon | #37 |
| tears tumor | #37 |
| contact lens surface | #37 |
| tenon anesthesia | #37 |
| schirmer 1 test | #37 |
| 002 mitomycin | #38 |
| post cataract | #38 |
| phacoemulsification implantation | #38 |
| cac japanese | #38 |
| pemirolast | #38 |
| device eye | #38 |
| gland lipid | #38 |
| aged olopatadine | #38 |
| exhibited correlation | #38 |
| allergic cromolyn | #38 |
| tests diagnostic accuracy | #39 |
| cells conjunctiva | #39 |
| patients dry eye | #39 |
| cyclosporine dry | #39 |
| infiltration corneal | #39 |
| tears eye | #39 |
| response pretreatment | #39 |
| conjunctiva limbus | #39 |
| degree 20 | #39 |
| solutions patient | #39 |
| atopic dry | #39 |
| 005 oct | #39 |
| 0001 specimens | #39 |
| accommodating intraocular | #39 |
| samples eyes | #40 |
| eye patients | #40 |
| decreased inflammation | #40 |
| subjects specimens | #40 |
| drops corneal | #40 |
| endothelial rejection | #40 |
| biomarkers conjunctiva | #40 |
| tmh | #40 |
| acid chemokine | #40 |
| pharmacology clinical efficacy | #40 |
| ulcers control | #40 |
| α pge2 | #41 |
| conjunctivitis gpc | #41 |
| treated topical | #41 |
| il1beta vegf | #41 |
| pollution severe | #41 |
| eyes superior | #41 |
| epitheliopathy | #41 |
| treatment dry | #41 |
| vegf il1beta | #41 |
| ecp concentrations | #41 |
| homologous visual | #41 |
| stimulate vascular | #41 |
| scans underwent | #42 |
| corneal epithelia | #42 |
| efficient noninvasive | #42 |
| october july | #42 |
| allergens conjunctivitis | #42 |
| day eye | #42 |
| break time | #42 |
| rollable | #43 |
| revised 2010 | #43 |
| keratolimbal | #43 |
| hydrocarbons data | #43 |
| cytology revealed | #43 |
| conjunctival hyperemia | #43 |
| microscopy central | #43 |
| diseases 2017 | #43 |
| instability decreased | #43 |
| limbus corneal | #43 |
| eyelid edema | #43 |
| meniscus treatment | #43 |
| surface years | #43 |
| eye 0001 | #44 |
| elasticity patients | #44 |
| agents keratoconjunctivitis | #44 |
| abovementioned drugs | #44 |
| activated il4 | #44 |
| tryptase par2 | #44 |
| collagens fibronectin | #44 |
| subjective symptom | #44 |
| tear meniscus | #44 |
| patients rhinoconjunctivitis | #44 |
| epithelial defect | #44 |
| oct assessment | #44 |
| il1beta il4 | #44 |
| tacrolimus treatment | #44 |
| cautery female | #44 |
| topical tacrolimus treatment | #45 |
| surgery uncorrected | #45 |
| case corneal | #45 |
| users contact | #45 |
| laser microscopy | #45 |
| graded 3 | #45 |
| fibroblasts eosinophils | #45 |
| recruiting chemokines | #45 |
| 24 seconds | #45 |
| micafungin mcfg | #45 |
| japan particulate | #45 |
| superficial punctate keratitis | #45 |
| surface inflammation | #45 |
| signs score | #45 |
| elevation iop | #45 |
| bovine enteric | #45 |
| inflammation ocular surface | #45 |
| formation corneal | #45 |
| rose bengal staining | #45 |
| adult chemotaxis | #45 |
| metaplasia grade | #45 |
| understanding ocular | #45 |
| metaplasia mucin | #45 |
| body sensation | #45 |
| fibroblasts expression | #45 |
| fourgrade scale | #45 |
| correlation inflammation | #45 |
| graticule | #46 |
| conjunctival | #46 |
| status ocular | #46 |
| seconds controls | #46 |
| tryptases regulation | #46 |
| efficacy combined therapy | #46 |
| corneal cells | #46 |
| surface disease | #46 |
| efficacy 01 | #46 |
| 17 japanese patients | #46 |
| fluorometholone | #46 |
| suspension effective | #46 |
| staining inflammatory | #46 |
| staining conjunctival | #46 |
| posttreatment findings | #46 |
| il13 serum | #46 |
| rate ocular | #47 |
| purpose efficacy | #47 |
| blood level | #47 |
| suspension 4 | #47 |
| diameter plant | #47 |
| patients 01 | #47 |
| allergic female histamine | #47 |
| positive muc5ac | #47 |
| visante oct | #47 |
| ulcer score | #47 |
| stimulation chemokine | #48 |
| brush cytology specimens | #48 |
| enhanced benefits | #48 |
| muc5ac mrna | #48 |
| sac patients | #48 |
| eyelid warming | #48 |
| stromal nerve | #48 |
| cyclosporine ophthalmic | #48 |
| eyes month | #48 |
| complications corneal | #48 |
| implantation acrysof | #48 |
| dexamethasone anti | #48 |
| ocular signs | #49 |
| expression crth2 | #49 |
| trabeculectomy eyes | #49 |
| concentrations tears | #49 |
| fibroblasts incubated | #49 |
| visits air | #49 |
| eosinophils epithelium | #49 |
| 1cu | #49 |
| objective findings | #49 |
| tacrolimus female | #49 |
| male tears | #49 |
| cxc chemokine genes | #49 |
| adult ca125 | #49 |
| keratocytes fibroblasts | #49 |
| measuring corneal | #50 |
| ulcers purpose | #50 |
| dyes fluorophotometry | #50 |
| trabeculectomy mitomycin | #50 |
| disposable soft | #50 |
| 4 normal controls | #50 |
| meniscus height | #50 |
| total severity score | #50 |
| inflammation conjunctiva | #50 |
| decreased tear | #50 |
| test ocular | #50 |
| aged blinking | #50 |
| schirmers test | #50 |
| patient eyes | #50 |
| effects docosahexaenoic acid | #51 |
| crth2 expression | #51 |
| diagnosis dry | #51 |
| markers atopic | #51 |
| scls | #51 |
| lenses scls | #51 |
| ocular surface cells | #51 |
| cells brush | #51 |
| inflammation cataract | #51 |
| reduction score | #51 |
| members japan | #51 |
| periostin patients | #51 |
| biomarker diseases | #52 |
| reaction vehicle | #52 |
| inflammation decline | #52 |
| pcr tgf | #52 |
| examination parameters | #52 |
| atopic groups | #52 |
| stability corneal | #52 |
| severity objective | #52 |
| tears tomography | #52 |
| eyelid margins | #52 |
| eye normal | #52 |
| month initiation | #52 |
| differential eosinophil | #53 |
| stromal nerves | #53 |
| bromfenac | #53 |
| acuity values | #53 |
| obstructive mgd | #54 |
| lacrimal glands | #54 |
| presence rsv | #54 |
| chloride bak | #54 |
| limbic keratoconjunctivitis | #54 |
| suspension treatment | #54 |
| 005 month | #54 |
| oxidation adolescent | #54 |
| scores tear | #54 |
| vegf protein secretion | #54 |
| combinedtreatment | #55 |
| surface clinical | #55 |
| ocular signs symptoms | #55 |
| epithelial cells expression | #55 |
| conjunctiva drug | #55 |
| antagonists allergic | #55 |
| aged pollen | #55 |
| adult conjunctivitis | #55 |
| local cytokine production | #55 |
| atopic enterotoxins | #55 |
| solution placebo | #56 |
| atopic patients | #56 |
| eosinophil cationic | #56 |
| mechanism giant | #56 |
| plant pollens | #56 |
| 3 dry | #56 |
| allergies adolescent | #56 |
| topical adolescent | #56 |
| ded adult | #56 |
| dysfunction atopic | #56 |
| mucin2 mucin4 | #56 |
| pain photophobia | #56 |
| mucin layer | #56 |
| film ocular | #56 |
| specular microscopic | #56 |
| cornea cyclooxygenase | #56 |
| accommodating iol | #57 |
| inflammation pge2 | #57 |
| penetrating limbus | #57 |
| chemotactic responses | #57 |
| humans interleukin4 | #57 |
| insensible administration | #57 |
| giant papillary conjunctivitis | #57 |
| papilla formation | #58 |
| schiff staining | #58 |
| drop treatment | #58 |
| objective sign | #58 |
| alpha defensins | #58 |
| maximum blood concentration | #58 |
| staining tear | #58 |
| seventyeight eyes | #58 |
| intraoperative mitomycin | #59 |
| tear instability | #59 |
| type allergic | #59 |
| findings criteria | #59 |
| disease eyes | #59 |
| pm25 prevalence | #59 |
| release inhibitor | #60 |
| mmc 2 | #60 |
| signs severe | #60 |
| pcr severe | #60 |
| compared 0001 | #60 |
| diabetic corneal | #60 |
| tacrolimus ointment treatment | #60 |
| daily disposable | #60 |
| syndromes female | #60 |
| evaluation items | #60 |
| nonsteroidal blotting | #61 |
| punctal | #61 |
| correlation patients | #61 |
| thermography adult | #61 |
| values tended | #62 |
| amplitude accommodation | #62 |
| combination epithelium | #62 |
| specimens histopathologic | #62 |
| total clinical | #62 |
| eyes 16 | #62 |
| prostaglandin patients | #62 |
| eotaxin1 expression | #62 |
| allergen mediated | #62 |
| expression eyes | #62 |
| conjunctiva patients | #63 |
| corneal erosion | #63 |
| corneal stem | #63 |
| sac age | #63 |
| il4 role | #63 |
| patient corneal | #63 |
| ulcer endophthalmitis | #63 |
| micafungin treatment | #63 |
| hypersensitivity japan | #63 |
| chamber body | #63 |
| oral pilocarpine | #63 |
| factor allergic | #64 |
| positive mucin | #64 |
| radioimmunoassay respiratory | #64 |
| evaluation corneal | #64 |
| il4 culture | #64 |
| cornea dry | #64 |
| eye adolescent | #64 |
| density inflammatory | #64 |
| dexamethasone production | #64 |
| live rsv | #65 |
| mucins rna | #65 |
| dust house | #65 |
| microscope methods | #65 |
| conclusions corneal | #65 |
| viral radioimmunoassay | #65 |
| tears biomarkers | #65 |
| diagnosis therapies | #66 |
| cases atopic | #66 |
| treatment immunosuppressive agents | #66 |
| layer speed | #66 |
| surface epithelial | #66 |
| cyclosporine eye | #67 |
| female fluorophotometry | #67 |
| agents keratoplasty | #67 |
| persistent epithelial | #67 |
| effects 01 | #67 |
| 003 treatment | #67 |
| period oral | #67 |
| time vital | #68 |
| housedust | #68 |
| ointment treatment | #68 |
| eye dry | #68 |
| occlusion 005 | #69 |
| ophthalmic solutions | #69 |
| fibroblasts examined | #69 |
| fibroblasts corneal | #69 |
| aged tears | #69 |
| patients eosinophils | #69 |
| counter drugs | #69 |
| glaucoma graft | #69 |
| schirmer test | #70 |
| crth2 receptor | #70 |
| 22 eyes | #70 |
| values rose | #70 |
| crth2 pgd2 | #70 |
| 1436 patients | #70 |
| rhinoconjunctivitis allergic | #70 |
| visit 4 | #70 |
| dust 20 | #71 |
| allergic dermatitis | #71 |
| factors tears | #71 |
| lenses dry | #71 |
| drops treatment | #71 |
| ige eosinophil | #72 |
| glaucoma trabeculectomy | #72 |
| bulbar conjunctiva | #72 |
| tear production | #72 |
| 16 eyes | #72 |
| fml | #73 |
| liquid conjunctiva | #73 |
| fluorophotometry humans | #73 |
| extraction conjunctiva | #73 |
| pollution prevalence | #73 |
| antiallergic agent | #73 |
| epithelial structure | #73 |
| surface mucins | #73 |
| punctate keratopathy | #73 |
| pyridines pyrimidinones | #73 |
| immunosuppressive treatment patients | #73 |
| agents intraocular | #74 |
| mcfg | #74 |
| iol acrysof | #74 |
| tacrolimus patients | #74 |
| evaluation dry | #74 |
| eosinophils expressed | #74 |
| inflammatory cell numbers | #74 |
| completely controlled | #75 |
| improved infrared | #75 |
| pilocarpine prospective | #75 |
| dust epidemiologic | #75 |
| 1 month baseline | #75 |
| laser flare | #75 |
| healthy individuals patients | #75 |
| cedar pollen | #75 |
| guidelines allergic | #76 |
| agents interleukin4 | #76 |
| ccchemokine | #76 |
| interleukin4 rna | #76 |
| cytokines stimulate | #77 |
| chemical mediator | #77 |
| surgery technique | #77 |
| cornea module | #77 |
| capilia | #77 |
| vegf tgfbeta1 | #77 |
| excision recurrence | #77 |
| cytology samples | #77 |
| ophthalmological elasticity | #77 |
| studies suspensions | #77 |
| signs treatment | #77 |
| lower tear | #77 |
| slight elongation | #77 |
| signs observed | #78 |
| drops 1 | #78 |
| concomitant tacrolimus | #78 |
| concentration il2 | #78 |
| pollen compared | #78 |
| japanese guideline | #78 |
| severity ocular | #78 |
| inhibitors leupeptin | #79 |
| type allergy | #79 |
| ocular pain | #79 |
| dry eye | #79 |
| glaucoma penetrating | #79 |
| il4 ige | #79 |
| extended wear | #79 |
| permeability cornea | #79 |
| allergic environmental | #79 |
| injection reduction | #79 |
| effects corneal | #79 |
| mediated par2 | #80 |
| mgd patients | #80 |
| medications required | #80 |
| questionnaires tears | #80 |
| assay epithelial | #80 |
| vegf concentration | #81 |
| antigens histamine | #81 |
| decreased dry | #81 |
| patients conjunctivitis | #82 |
| acrysof iol | #82 |
| prostaglandin reverse | #82 |
| caused insufficient | #82 |
| cytology performed | #82 |
| atopic dermatitis study | #82 |
| complications lenses | #83 |
| expression corneal | #83 |
| patients staphylococcus aureus | #83 |
| dental college | #83 |
| tear lipid | #83 |
| data tacrolimus | #83 |
| epithelium ocular | #84 |
| earlier published data | #84 |
| cytokines vegf | #84 |
| schirmer | #84 |
| correlation corneal | #84 |
| papillae | #84 |
| treatment odds ratio | #85 |
| inhibitors tryptases | #85 |
| patients dry | #85 |
| alterations basal | #85 |
| 18 pg | #85 |
| human reverse | #85 |
| combined penetrating | #85 |
| 5 grades | #85 |
| scleritis patients | #85 |
| temperature patients | #85 |
| hyperemia induced | #85 |
| discharge evaluated | #86 |
| sligkv | #86 |
| inflammation eye | #86 |
| pharmacologic intervention | #86 |
| daily outpatient | #86 |
| acuity accommodation | #86 |
| edema scores | #86 |
| 284 years | #86 |
| patients eyelid | #86 |
| tacrolimus young | #87 |
| detection limit assay | #87 |
| confocal ophthalmic | #87 |
| tacrolimus reduced | #87 |
| sclera surgical | #88 |
| tears | #88 |
| post keratoplasty | #88 |
| disease conjunctiva | #88 |
| cells keratocytes | #88 |
| daily weather conditions | #88 |
| regulation muc5ac | #88 |
| seasonal perennial | #89 |
| tryptase inhibitors | #89 |
| tears visual | #89 |
| eyes 30 | #89 |
| findings severe | #89 |
| assessment dry | #89 |
| months signs | #90 |
| early ocular | #90 |
| temperature cornea | #90 |
| decrease corneal | #90 |
| dressings chronic | #90 |
| tears adult | #90 |
| glands microscopy | #90 |
| lower corneal | #90 |
| cytocentrifuge preparations | #90 |
| film breakup | #91 |
| lenses extended | #91 |
| techniques trabeculectomy | #92 |
| eye corneal | #92 |
| procedures phacoemulsification | #92 |
| exposure japan | #92 |
| laser cell | #92 |
| treatment noninfectious | #93 |
| 7 visit | #93 |
| conjunctival specimens | #93 |
| drug fibroblasts | #93 |
| patients correlation | #93 |
| stromal corneal | #93 |
| solutions tears | #93 |
| eye cataract surgery | #93 |
| 005 complications | #93 |
| regulation muc1 | #93 |
| preschool conjunctiva | #93 |
| tears administration | #93 |
| case allergic | #94 |
| classification pathogenesis | #94 |
| pgd2 crth2 | #94 |
| reaction physical | #94 |
| pollution weather | #94 |
| exposure exhaust | #94 |
| eye higher | #95 |
| twentyeight eyes | #95 |
| studies tears | #95 |
| eosinophils patients | #95 |
| induced pgd2 | #95 |
| relevant factor | #95 |
| staining fluorescein | #96 |
| protein eosinophilia | #96 |
| study cyclosporine | #96 |
| score objective | #96 |
| 128 eyes | #96 |
| higher eyes | #96 |
| production pge2 | #97 |
| cells hel | #97 |
| 4 alterations | #97 |
| 1month treatment | #97 |
| treatment ecp | #97 |
| eyes study | #98 |
| staining schirmer | #98 |
| eyes positive | #98 |
| vdts | #98 |
| meniscus patients | #98 |
| eye tear | #98 |
| pseudophakic patients | #99 |
| cytology evaluation | #99 |
| equivalent 4 | #99 |
| solution improved | #99 |
| 005 recurrence | #99 |
| japan post | #99 |
| management ocular | #99 |
| surgery 6 months | #99 |
| cells severity | #100 |
| confocal scanning | #100 |
| postoperatively statistically | #100 |
| corneal abnormalities | #100 |
| ointments tacrolimus | #100 |
| allergic atopic | #100 |
| terminals contact | #100 |
| conjunctiva corneal | #100 |
| local pattern | #100 |
| ulcer patient | #100 |
| pathogenesis atopic | #101 |
| fibroblasts 2 | #101 |
| eyes 10 | #101 |
| disease classified | #102 |
| pathogenesis allergic | #102 |
| therapy conjunctival | #102 |
| severe atopic | #102 |
| agents conjunctivitis | #102 |
| keratolimbal allograft | #102 |
| effects tranilast | #102 |
| prevalence dry | #103 |
| washing solution | #103 |
| chemotaxis experiments | #103 |
| mediated protease | #103 |
| subjective comfort | #103 |
| topic premedication | #104 |
| groups dry | #104 |
| values vital | #104 |
| events scores | #104 |
| differences ocular | #104 |
| topical cyclosporine | #104 |
| patients bf | #104 |
| syndrome epstein | #104 |
| allergic cytokines | #104 |
| tears young | #104 |
| aged amnion | #105 |
| baseline initiation | #105 |
| child conjunctival | #105 |
| role staphylococcal | #105 |
| wearing contact | #105 |
| inflammation diagnosis | #105 |
| conjunctival impression cytology | #105 |
| pressure keratoplasty | #106 |
| conjunctiva cornea | #106 |
| microscopy evaluation | #106 |
| parameters ocular | #106 |
| 14 eyes | #106 |
| adhesion fibroblasts | #106 |
| superficial punctate | #107 |
| eotaxin1 | #107 |
| patients ded | #107 |
| corneal keratocytes | #107 |
| induces chemotaxis | #108 |
| film instability | #108 |
| scores symptoms | #108 |
| resins aged | #108 |
| conjunctiva | #108 |
| topical tacrolimus | #108 |
| acuity acrylic | #108 |
| levels radioimmunoassay | #108 |
| dry mouth symptoms | #108 |
| lipid layer | #108 |
| asian dust | #109 |
| 4 dry | #109 |
| effects dha | #109 |
| corneal inflammatory | #109 |
| level tacrolimus | #109 |
| tear evaporation | #109 |
| il4 human | #109 |
| increased evaporation | #110 |
| dysfunction mgd | #110 |
| controls inflammatory | #110 |
| eyes 9 | #110 |
| conjunctival epithelium | #110 |
| steroids administration | #110 |
| lacrimal salivary | #110 |
| japanese guidelines | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| eye camera | #112 |
| vcam1 antibody | #112 |
| anterior segment inflammation | #113 |
| dibenzoxepins | #113 |
| strabismus surgery | #113 |
| pcr rsv | #113 |
| solutions platelet | #113 |
| papillary conjunctivitis | #113 |
| grading scores | #114 |
| diagnosed allergic | #114 |
| layer patients | #114 |
| lesions atopic | #114 |
| incision cataract | #114 |
| eye irritation | #114 |
| male mucin | #115 |
| findings severity | #115 |
| 13 eyes | #115 |
| conjunctival cell | #115 |
| sjögrens syndrome patients | #115 |
| allergic eye | #115 |
| seconds 0001 | #115 |
| goblet cell density | #115 |
| cholinergic treatment | #115 |
| edition revised | #116 |
| selective histamine | #116 |
| viscosupplements aged | #117 |
| ophthalmology prevalence | #117 |
| patients seasonal | #117 |
| metaplasia mucins | #117 |
| asia dust | #117 |
| cooling increased | #117 |
| samples stained | #117 |
| sag genes | #118 |
| effects docosahexaenoic | #118 |
| molecule1 interleukin4 | #118 |
| generation pge2 | #118 |
| immunologic receptors prostaglandin | #118 |
| revealed higher | #119 |
| 39 mmhg | #119 |
| chemotaxis induced | #119 |
| week 005 | #119 |
| skin elasticity | #119 |
| iop observed | #119 |
| acuity distance | #119 |
| topical steroids | #119 |
| matter prevalence | #120 |
| syndromes epithelium | #120 |
| levels histamine | #121 |
| distance corrected | #121 |
| mitomycinc mmc | #121 |
| mitomycin ophthalmic | #121 |
| soft lenses | #121 |
| chronic allergic | #122 |
| adult conjunctiva | #123 |
| titers ebv | #123 |
| collagen conjunctiva | #123 |
| artificial tear | #123 |
| male ointments | #123 |
| area corneal | #124 |
| eosinophils cell | #124 |
| activity corneal | #125 |
| conjunctival tissues | #125 |
| month reduced | #126 |
| proteaseactivated receptor2 | #126 |
| damage severe | #126 |
| patients atopic | #127 |
| subjects vivo | #127 |
| 05ng | #127 |
| nerves studied | #127 |
| soft contact lenses | #128 |
| 9 genes | #128 |
| gamma increase | #128 |
| elisa levels | #129 |
| acds | #129 |
| combination steroids | #129 |
| fibroblast viability | #129 |
| 361 ± | #129 |
| fva | #130 |
| functional visual | #130 |
| patients insignificant | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| cataract phacoemulsification | #132 |
| 5ac | #132 |
| management allergic | #132 |
| resection severe | #132 |
| eyes fluorescein | #132 |
| eye drop | #132 |
| proteins mucin | #133 |
| treated tacrolimus | #133 |
| 19 normal subjects | #133 |
| keratoplasty adult | #133 |
| skin water | #133 |
| gene transcription levels | #133 |
| normal conjunctival | #134 |
| surface examination | #134 |
| acrylic iol | #134 |
| density negative | #134 |
| pcr hla | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| stress status | #136 |
| iop treatment | #136 |
| ocular surface | #137 |
| dry eye patients | #137 |
| eosinophil adhesion | #137 |
| antiallergic properties | #137 |
| ophthalmological dry | #137 |
| severity 10 | #137 |
| iol groups | #138 |
| eosinophil cationic protein | #138 |
| asian dust storms | #138 |
| ratio remission | #139 |
| authors technique | #139 |
| allergic dogs | #139 |
| protein ecp | #139 |
| suppressed pretreatment | #140 |
| aminobenzoates anti | #141 |
| allergic patients | #141 |
| inflammation prostaglandin | #141 |
| interleukin1 interleukin13 | #142 |
| improvements symptom | #142 |
| findings upper | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| 52 mmhg | #144 |
| determine central | #144 |
| studies scleritis | #144 |
| cornea cyclosporine | #144 |
| recordable | #145 |
| symptoms ocular | #145 |
| eye syndromes | #145 |
| specimens patient | #145 |
| underwent evaluation | #146 |
| eye clinical | #146 |
| virus pathogen | #146 |
| fibroblasts alpha | #146 |
| reticular basement membrane | #146 |
| schiff reaction | #146 |
| findings adolescent | #146 |
| human conjunctiva | #146 |
| hne 4 | #147 |
| required type | #147 |
| diagnosis atopic | #147 |
| 263 years | #147 |
| dscg | #147 |
| impression cytology | #147 |
| ulcer drug | #148 |
| increased goblet | #148 |
| dynamic visual acuity | #148 |
| 0001 corneal | #148 |
| fibroblasts production | #149 |
| concentration tacrolimus | #149 |
| quantitative evaluation | #149 |
| intraocular lens iol | #149 |
| cationic protein | #149 |
| suspension based | #149 |
| patients allergic | #149 |
| japan phenotype | #149 |
| inflammatory cells | #150 |
| pyrimidinones treatment | #150 |
| japanese cedar pollen | #150 |
| controls performed | #151 |
| inflammation reduction | #151 |
| tacrolimus treated | #152 |
| par2 reverse | #152 |
| postoperative secondary | #152 |
| 28 surgery | #153 |
| eyes 11 | #153 |
| symptoms objective | #153 |
| artificial tears | #153 |
| induced eotaxin | #153 |
| increased fibroblasts | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| male mitomycin | #155 |
| inflammation ocular | #155 |
| alcon | #156 |
| eyelids female | #156 |
| association pm25 | #156 |
| chemokine expression | #156 |
| ointments skin | #157 |
| analysis prostaglandin | #157 |
| rates untreated | #157 |
| greater inflammation | #157 |
| values improved | #157 |
| inflammatory ocular | #157 |
| pcr increase | #157 |
| lipid infiltration | #157 |
| trial tacrolimus | #158 |
| surface status | #158 |
| acuities | #158 |
| japan included | #158 |
| immunological characteristics | #159 |
| weeks adverse | #159 |
| 3 boys | #159 |
| study inflammation | #160 |
| mucin 5ac | #161 |
| acid schiff | #161 |
| thirtysix eyes | #161 |
| chemokines production | #161 |
| 28 female | #161 |
| elevation study | #161 |
| muc16 | #161 |
| bromobenzenes | #162 |
| surgery topical | #162 |
| 326 years | #162 |
| distance visual acuity | #162 |
| male meibomian | #162 |
| studied 21 | #163 |
| il1beta il2 | #163 |
| prevalence ocular | #163 |
| oxidative stress status | #163 |
| olopatadine | #163 |
| twentynine eyes | #163 |
| visit 7 | #163 |
| efficacy tacrolimus | #163 |
| steroid anti | #164 |
| purpose reported | #164 |
| soft contact | #164 |
| 002 treatment | #164 |
| patients topical | #164 |
| spt positive | #164 |
| 30ng | #164 |
| biological dressings | #165 |
| production prostaglandin | #165 |
| cytometry hla | #166 |
| pgd2 induced | #166 |
| fluorescein humans | #166 |
| cytokines allergic | #167 |
| eosinophils higher | #167 |
| tacrolimus ointment | #167 |
| males 5 | #168 |
| ulcers erosions | #168 |
| 12 males | #169 |
| treating refractory | #169 |
| eotaxin chemokine | #169 |
| local allergic | #169 |
| patients postsurgical | #169 |
| seldi | #169 |
| studies tacrolimus | #169 |
| steroidal blotting | #169 |
| expression chemokines | #170 |
| conjunctiva conjunctival | #171 |
| management enzyme | #171 |
| status inflammation | #171 |
| subbasal nerve | #172 |
| palisades | #173 |
| fibroblasts fibroblast | #173 |
| vivo confocal | #174 |
| slit lamp | #174 |
| status oxidative | #174 |
| distance acuity | #174 |
| standard conventional | #174 |
| subjective symptoms | #174 |
| pcr flow | #174 |
| postkeratoplasty | #175 |
| 34 eyes | #175 |
| homologous molecule | #176 |
| evaluated symptoms | #176 |
| subbasal | #177 |
| aldehydes biomarkers | #177 |
| dust extract | #177 |
| treatment corneal | #177 |
| study longterm outcomes | #177 |
| tryptase | #178 |
| strabismus adolescent | #178 |
| reduction intraocular pressure | #178 |
| endophthalmitis female | #178 |
| mild 2 | #178 |
| acrysof | #178 |
| chemokine genes | #179 |
| risk ocular | #179 |
| migration eosinophils | #180 |
| 4 female | #180 |
| dyes follow | #180 |
| myopic regression | #180 |
| compared eye | #180 |
| japan young adult | #180 |
| ceramides child | #180 |
| cutometer | #181 |
| normal control patients | #181 |
| lipid study | #181 |
| serum il4 | #183 |
| lipoproteins micafungin | #183 |
| blepharitis | #183 |
| male radioallergosorbent | #184 |
| mucin4 mucins | #185 |
| igg virus | #185 |
| human lymphocyte antigen | #185 |
| nerve prospective | #186 |
| examined parameters | #186 |
| therapy corneal | #186 |
| atopic eosinophils | #187 |
| drug fibroblasts humans | #187 |
| par2 mrna | #187 |
| efficacy topical | #187 |
| corneal fibroblasts | #187 |
| suspensions administration | #187 |
| corneal sensitivity | #188 |
| eye symptoms | #188 |
| il13 increased | #188 |
| 19 eyes | #188 |
| production stromal | #189 |
| allergic cross | #189 |
| sensitivity regulation | #189 |
| seconds patients | #189 |
| levels 33 | #190 |
| effects diesel | #191 |
| assisted infrared | #191 |
| tear break | #191 |
| infiltrating eosinophils | #191 |
| improvement subjective | #192 |
| controls vivo | #193 |
| allergic rhinoconjunctivitis | #193 |
| therapeutic study | #193 |
| 26 eyes | #194 |
| expression rantes | #195 |
| fibroblasts inhibited | #195 |
| reactivation epstein | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| treatment topical | #197 |
| 80 allergens | #197 |
| eyes 21 | #197 |
| interleukin4 production | #197 |
| methods primary | #197 |
| tear film stability | #197 |
| combination topical | #198 |
| tears time | #198 |
| elisa performed | #198 |
| 28 eyes | #198 |
| effects topical | #199 |
| pollen prospective | #199 |
| preservative free | #201 |
| photorefractive keratectomy | #201 |
| pollen allergic | #201 |
| mcp1 ip10 | #201 |
| perennial allergic | #201 |
| receptor homologous | #202 |
| hypersensitivity interleukin13 | #202 |
| unit density | #202 |
| rsv infected | #202 |
| eosinophils neutrophils | #203 |
| grade scale | #204 |
| differences iop | #204 |
| vcam1 icam1 | #204 |
| ova alum | #204 |
| pge2 human | #204 |
| inflammatory allergic | #205 |
| eyes 005 | #205 |
| eyes cataract | #206 |
| time tbut | #206 |
| minutes 8 | #206 |
| disease acd | #206 |
| disease dry | #206 |
| crth2 | #207 |
| count cornea | #207 |
| pressure lens | #207 |
| ecp levels | #207 |
| glands middle | #207 |
| formation giant | #207 |
| mammalian milk | #208 |
| fluorescein fluorescent | #208 |
| tears aged | #208 |
| size contact | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| treatment allergic | #210 |
| human allergic | #210 |
| month reduction | #210 |
| antiallergic drug | #211 |
| oct diagnosis | #211 |
| refractory conventional | #211 |
| inflammation injection | #212 |
| iol patients | #212 |
| tacrolimus combination | #212 |
| combination tests | #212 |
| treated refractory | #213 |
| chamber anti | #213 |
| conjunctiva eye | #213 |
| steroids treatment | #214 |
| muc5ac | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| expressions higher | #219 |
| nuclear cataract | #219 |
| august october | #220 |
| conjunctival biopsy | #220 |
| metabolism lysine | #220 |
| tranilast | #220 |
| findings inflammation | #221 |
| conjunctivitis acute | #221 |
| samples correlated | #222 |
| combined therapy | #222 |
| cells crth2 | #222 |
| level ambient | #222 |
| diseases dry | #222 |
| twentyfour eyes | #222 |
| symptoms short | #224 |
| iop corneal | #224 |
| sensitivity measurements | #224 |
| 26 control subjects | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| treatment 3 months | #228 |
| corneal clarity | #228 |
| eyes adult | #228 |
| itching | #229 |
| followup cases | #229 |
| corrected distance | #230 |
| eye signs | #230 |
| treatment superior | #230 |
| activity eosinophils | #231 |
| exhaust particles | #231 |
| 30 eyes | #231 |
| examined level | #232 |
| alpha defensin | #232 |
| scleral flap | #232 |
| events initiation | #232 |
| concomitantly administered | #233 |
| proteinchip | #233 |
| dye staining | #233 |
| cyclosporine treatment | #233 |
| 791 patients | #233 |
| anti allergic | #233 |
| 644 years | #234 |
| cultured eosinophils | #235 |
| examined production | #235 |
| specimens patients | #236 |
| corneal disease | #236 |
| quantitatively evaluate | #236 |
| gamma transcripts | #237 |
| term topical | #237 |
| topical steroid | #238 |
| tool quantitative | #240 |
| diagnostic abilities | #240 |
| studied subjects | #240 |
| proliferative lesions | #240 |
| eyes ocular | #241 |
| bf patients | #241 |
| surface lipid | #242 |
| cromolyn sodium | #242 |
| cell chemotactic | #242 |
| performed higher | #245 |
| common ocular | #245 |
| specular microscopy | #246 |
| eye drops | #247 |
| subjects males | #247 |
| equivalent 2 | #247 |
| chemosis | #248 |
| specificity cutoff | #248 |
| failure visual | #250 |
| labeling intercellular | #251 |
| response prostaglandin | #251 |
| males 13 | #252 |
| seasonal allergic | #252 |
| syndrome tears | #252 |
| leukocyte child | #252 |
| subjective objective | #252 |
| topical oral | #253 |
| levels tacrolimus | #253 |
| muc | #255 |
| improved vision | #255 |
| corneal female | #255 |
| stability positive | #256 |
| rantes expression | #256 |
| dexamethasone inhibition | #256 |
| treating severe | #257 |
| disease corneal | #257 |
| eosinophil chemotaxis | #258 |
| tear | #259 |
| questionnaire objective | #259 |
| month treatment | #260 |
| eyes control | #260 |
| additional medications | #260 |
| eosinophil infiltration | #260 |
| role histamine | #260 |
| expression rsv | #261 |
| human transcription | #261 |
| smaller normal | #262 |
| h1 antagonist | #262 |
| aged mucin | #264 |
| severity adverse | #264 |
| 1 month treatment | #264 |
| immunohistochemistry increased | #264 |
| keratoplasty pkp | #265 |
| steroid induced | #265 |
| eyelid diseases | #266 |
| controls p0001 | #266 |
| signs blood | #267 |
| data weekly | #267 |
| treatment atopic | #268 |
| microscopy negative | #268 |
| studied production | #268 |
| patients sjögren syndrome | #268 |
| respiratory syncytial virus | #268 |
| sodium drug | #269 |
| aged aldehyde | #270 |
| computer terminals | #270 |
| h1 histamine | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| improved visual acuity | #273 |
| 13 males | #273 |
| aldose reductase inhibitor | #273 |
| epithelium endothelium | #274 |
| combination eosinophils | #274 |
| concentration quantitative | #274 |
| studies stevens | #274 |
| meibomian gland dysfunction | #275 |
| patients sjögren | #277 |
| meibomian gland | #277 |
| tear breakup time | #277 |
| tbut | #278 |
| individuals pcr | #278 |
| grading score | #278 |
| 13 females | #279 |
| 0001 diagnosis | #279 |
| eyes 14 | #279 |
| bloodaqueous barrier | #279 |
| interleukin il4 | #280 |
| multifunctional glycoprotein | #280 |
| 10 seconds | #281 |
| required provide | #281 |
| cautery | #282 |
| expressed th2 | #282 |
| disease purpose | #282 |
| gland dysfunction | #284 |
| ige positive | #284 |
| contralateral eye | #285 |
| amniotic membrane | #285 |
| atopic | #286 |
| seasons adolescent | #286 |
| th2 cytokines | #287 |
| layer adult | #288 |
| cases refractory | #288 |
| study tacrolimus | #289 |
| adult alkylating | #289 |
| eyedrops | #291 |
| entericcoated | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| treatment 01 | #294 |
| new antifungal | #294 |
| exponential equation | #294 |
| levels ige | #295 |
| single therapy | #295 |
| serum periostin | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| ccl11 chemokine | #300 |
| severity diagnosis | #300 |
| rose bengal | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| cobblestone | #303 |
| moderate 3 | #303 |
| assessed based | #303 |
| scanning laser | #304 |
| photophobia | #304 |
| initiation treatment | #305 |
| scores worse | #305 |
| operation patient | #305 |
| piperidines treatment | #306 |
| eczema severity | #306 |
| membrane patch | #307 |
| assessed 4 | #307 |
| gel application | #308 |
| evaluation groups | #309 |
| interleukin13 interleukin2 | #309 |
| 10 normal subjects | #309 |
| compared simple | #310 |
| comfort level | #310 |
| inflammatory cell | #310 |
| slitlamp examination | #311 |
| treatment seasonal | #311 |
| 12 eyes | #311 |
| regard age | #311 |
| cytology specimens | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| aged staining | #315 |
| eye adult | #315 |
| child corneal | #316 |
| 19 normal | #316 |
| cells cornea | #317 |
| interferometry light | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| fluorophotometry | #320 |
| prospective singlearm study | #320 |
| dermatitis clinical | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| bilateral cataracts | #323 |
| ulcers | #323 |
| agreement weighted | #324 |
| pollen allergen | #324 |
| 15 30 minutes | #325 |
| eyes 19 | #325 |
| icam1 vcam1 expression | #326 |
| 095 ± | #326 |
| surgery diabetic | #327 |
| chemokine concentrations | #327 |
| transplantation corneal | #328 |
| expression goblet | #329 |
| icam1 antibody | #329 |
| insensible | #330 |
| treatment 2 weeks | #331 |
| pressure ocular | #331 |
| dry eye disease | #332 |
| receptors il2r | #332 |
| leukocyte coculture | #333 |
| eye treated | #335 |
| cornea diagnostic | #335 |
| values daily | #335 |
| proprietary | #336 |
| 27 eyes | #337 |
| male staphylococcal | #337 |
| corneal epithelial | #337 |
| signs clinical | #339 |
| daily wear | #339 |
| levels epithelial | #341 |
| eyes 27 | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| measurements treatment | #347 |
| corneal infection | #347 |
| induced elevation | #348 |
| eyes 13 | #348 |
| expression eosinophils | #348 |
| surgery eye | #350 |
| test values | #350 |
| contrast visual | #352 |
| surface diseases | #352 |
| iop elevation | #353 |
| weekly average | #354 |
| expression allergic | #354 |
| incidence allergic | #355 |
| temperature infrared | #355 |
| examination serum | #356 |
| choroidal detachment | #356 |
| patients allergy | #357 |
| tear film | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| tacrolimus tumor | #359 |
| months conventional | #359 |
| subjects 13 | #361 |
| difference efficacy | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| function laser | #368 |
| treatment ocular | #368 |
| studies sclera | #368 |
| plant pollen | #368 |
| corneae male | #369 |
| mucin1 mucin2 | #370 |
| postoperative adhesion | #370 |
| eyes 17 | #370 |
| systemic control | #371 |
| inhibitors epithelium | #372 |
| cryptomeria japonica | #372 |
| sixteen eyes | #373 |
| periodic acid schiff | #374 |
| micafungin middle | #374 |
| improvement local | #375 |
| assessment severe | #375 |
| cornea female | #375 |
| extraction cell | #376 |
| retina tomograph | #376 |
| levels atopic | #377 |
| 10 normal | #377 |
| higher human | #377 |
| 4 lower | #377 |
| phacoemulsification prospective | #377 |
| treatment eyes | #378 |
| count child | #378 |
| tarsal | #378 |
| stimulation tnf | #380 |
| mitomycin | #380 |
| corneal inflammation | #381 |
| cornea eye | #381 |
| negative serum | #382 |
| inflammation epithelial | #383 |
| pollinosis | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| ocular diseases | #386 |
| corneal epithelial cells | #386 |
| limit assay | #388 |
| surgery 13 | #388 |
| surface alterations | #388 |
| decrease inflammatory | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| sde | #390 |
| severity incidence | #390 |
| antiallergic | #391 |
| patients proteins | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| 44 eyes | #395 |
| applied 5 | #395 |
| chronic ocular | #395 |
| relative percentages | #396 |
| opacity corneal | #396 |
| techniques interleukin4 | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| remission based | #400 |
| declaration helsinki | #400 |
| modified boyden | #401 |
| eyes severe | #401 |
| rays male | #402 |
| sedating humans | #403 |
| vogt | #404 |
| measurements oct | #404 |
| weather air | #404 |
| cells allergic | #404 |
| prospective controlled study | #405 |
| reproducibility surface | #406 |
| patients epithelial | #406 |
| 137 years | #407 |
| improved diagnosis | #407 |
| serum total ige | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| confocal | #412 |
| eyes 15 | #412 |
| specific total | #412 |
| acids fibroblasts | #412 |
| 3 months treatment | #413 |
| allergic reaction | #413 |
| counts 1 | #413 |
| keratocytes | #414 |
| limbal | #416 |
| postoperative inflammation | #416 |
| penetrating keratoplasty | #418 |
| central cornea | #418 |
| chemokine ccl11 | #419 |
| mucin4 | #419 |
| patients comfort | #419 |
| speed resolution | #419 |
| ophthalmologist | #420 |
| sjögren syndrome | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| clinical observation | #425 |
| 40 minutes | #425 |
| production 4 | #430 |
| trabeculectomy visual | #430 |
| staining score | #431 |
| rhinoconjunctivitis | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| performed immunohistochemistry | #437 |
| cedrus | #437 |
| 5 women | #438 |
| methods eye | #438 |
| regulation eye | #438 |
| commercial tests | #439 |
| foldable | #440 |
| subjects studied | #440 |
| interleukin4 il4 | #440 |
| vmr | #441 |
| fluorescein dye | #441 |
| regulation chemokine | #441 |
| landolt | #441 |
| females normal | #442 |
| anti vcam1 | #442 |
| adult aldehydes | #442 |
| male mucin1 | #444 |
| 17 males | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| male 4 | #450 |
| 30 serum | #450 |
| eye eyes | #451 |
| keratoplasty | #452 |
| wash | #452 |
| antagonists sedating | #453 |
| ketotifen | #453 |
| versus vehicle | #453 |
| surface disorder | #454 |
| normal patients | #454 |
| response allergens | #454 |
| vivo confocal microscopy | #454 |
| 8 genes | #455 |
| production clearance | #455 |
| water evaporation | #455 |
| ophthalmic nerve | #455 |
| agonists pilocarpine | #456 |
| humans keratoplasty | #456 |
| outpatient visits | #457 |
| normal controls patients | #457 |
| amnion cell | #457 |
| ocular risk | #457 |
| checker | #459 |
| oct study | #460 |
| greatest improvements | #461 |
| distance visual | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| unpaired ttest | #467 |
| fibroblasts tgf | #467 |
| study pcr | #468 |
| examination diagnosis | #469 |
| background atopic | #469 |
| major sources | #470 |
| allergy adult | #473 |
| markers severity | #473 |
| metry | #475 |
| hladr expression | #476 |
| diagnosis rate | #476 |
| 13 mmhg | #478 |
| pollen seasons | #478 |
| fibroblasts primary | #478 |
| height measurement | #480 |
| reduce clinical | #480 |
| newly formed vessels | #480 |
| subjects eyes | #481 |
| examined prospective | #482 |
| interleukin 13 | #482 |
| crystalline lens implantation | #485 |
| 21 eyes | #488 |
| accommodating | #488 |
| induced 15 | #489 |
| shortterm study | #490 |
| myopia photorefractive | #490 |
| disodium cromoglycate | #493 |
| ebv reactivation | #495 |
| prolonged inflammation | #495 |
| acuity intraocular | #495 |
| months eyes | #498 |
| corneal | #498 |
| il2 tumor | #499 |
| exposure diesel | #499 |
| stain positive | #499 |
| silicone hydrogel | #500 |
| lens iol | #500 |
| symptoms efficacy | #501 |
| infections viral | #501 |
| treatment eye | #502 |
| pge2 cox2 | #502 |
| studies status | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| eye position | #505 |
| 2 daily | #505 |
| correlate severity | #506 |
| airborne particulate matter | #506 |
| inflammatory status | #506 |
| penetrating male | #507 |
| induced ocular | #509 |
| aldose reductase | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| male water | #519 |
| inhibition production | #519 |
| observed baseline | #519 |
| lipopeptides lipoproteins | #520 |
| groups duration | #520 |
| chemoattractant receptor | #522 |
| 01 | #522 |
| metaregression analysis | #523 |
| infection rsv | #524 |
| 10 normal volunteers | #524 |
| dinoprostone epithelial | #525 |
| studies trabeculectomy | #525 |
| studies cornea | #527 |
| trabeculectomy | #527 |
| giemsa staining | #528 |
| density basal | #528 |
| rhodanine | #531 |
| itchy | #531 |
| serum antigen | #535 |
| ocular symptoms | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| patients cataract | #538 |
| total hydrocarbons | #538 |
| dependent migration | #539 |
| sac | #539 |
| capsular bag | #540 |
| placebo tablets | #540 |
| visit 6 | #541 |
| 80 anterior | #541 |
| administration topical | #542 |
| cases flow | #542 |
| infrared radiation | #543 |
| 20 normal | #543 |
| 6 male | #544 |
| ebv nuclear antigen | #546 |
| production cultured | #546 |
| time improved | #547 |
| pollution allergens | #549 |
| periodic acid | #549 |
| film layer | #550 |
| prospective comparative study | #550 |
| il‐4 | #552 |
| cryptomeria | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| fibroblasts response | #555 |
| genechip | #555 |
| disease ded | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| density assessed | #558 |
| transplantation combined | #558 |
| methods thirty | #559 |
| diesel exhaust particles | #559 |
| differentiation inflammatory | #560 |
| eyes iop | #560 |
| ocular infections | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| 16 age | #569 |
| count corneal | #569 |
| cultured corneal | #570 |
| levels il4 | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| 4 mrna | #580 |
| iop eyes | #580 |
| lesions normal | #582 |
| fibrosis fluorescent | #582 |
| apparatus male | #582 |
| department ophthalmology | #584 |
| increase vegf | #584 |
| tnfalpha stimulation | #584 |
| symptoms scores | #588 |
| intraocular male | #589 |
| hladr antigen | #589 |
| female humans allergic | #589 |
| patients csa | #589 |
| induced 4 | #589 |
| corneal epithelium | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| assay eye | #597 |
| findings evaluated | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| topical adult | #609 |
| inflammation status | #609 |
| thermography | #611 |
| corneal nerves | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| patients complained | #615 |
| antagonists humans | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| grades 0 | #617 |
| ocular allergy | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| lamp examination | #625 |
| glaucoma medications | #625 |
| years studied | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| burning sensation | #636 |
| redness | #636 |
| corneal haze | #636 |
| patients tacrolimus | #636 |
| total immunoglobulin | #638 |
| contact lenses | #639 |
| based severity | #639 |
| eosinophils | #639 |
| 511 patients | #640 |
| male rhinitis | #640 |
| development allergic | #641 |
| 11 eyes | #641 |
| symptoms signs | #643 |
| months 01 | #643 |
| performed modified | #643 |
| observed follow | #644 |
| fibrosis actins | #645 |
| mellitus double | #645 |
| patients healthy volunteers | #650 |
| 2 females | #651 |
| viscosupplements | #651 |
| expression administration | #651 |
| analysis existence | #654 |
| eosinophils flow | #654 |
| diseases methods | #656 |
| lacrimal | #657 |
| comfortable | #657 |
| patients elisa | #660 |
| 96well plate | #661 |
| nerve density | #661 |
| chamber technique | #662 |
| treatment 0001 | #664 |
| lens wearers | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| damage scores | #669 |
| 10 age | #669 |
| viruses acute | #669 |
| cedar | #672 |
| stimulation rna | #672 |
| 11 males | #673 |
| humans lacrimal | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| adherence anti | #681 |
| test methods | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| fibronectin cell | #684 |
| stainings | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| atopic female humans | #694 |
| cells eye | #694 |
| 1 test | #695 |
| inhibition expression | #697 |
| early antigen | #697 |
| cromolyn | #700 |
| levels detection | #700 |
| objective assessments | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| 1 month | #715 |
| fibroblasts flow | #715 |
| major characteristic | #717 |
| 5 eyes | #718 |
| key cells | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| aged ophthalmology | #730 |
| followup treatment | #730 |
| 11 male | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| reductase inhibitor | #737 |
| symptoms 5 | #737 |
| intraocular lens | #740 |
| density compared | #741 |
| keratectomy | #741 |
| expression real | #744 |
| definition classification | #746 |
| unpaired test | #746 |
| blood eosinophils | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| daily weather | #751 |
| cornea corneal | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| topical aged | #763 |
| intraocular lens implantation | #763 |
| trabeculectomy treatment | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| oligopeptides rna | #769 |
| pathogenesis severe | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| role allergic | #783 |
| levels prostaglandin | #783 |
| fluorescein fluoresceins | #784 |
| limbus corneae | #784 |
| blinking | #785 |
| purpose analyze | #785 |
| treatment 1 | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| lenses intraocular | #792 |
| eyes normal | #792 |
| increased epithelial | #793 |
| tacrolimus | #793 |
| techniques laminin | #793 |
| ocular inflammation | #794 |
| 4 hne | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| positive linear | #801 |
| report efficacy | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| receptors ccr3 | #813 |
| mucin | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| aged cell | #820 |
| concentration dose | #820 |
| cells eosinophils | #821 |
| interleukin4 | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| lymphocytes compared | #834 |
| preoperative level | #834 |
| surgical outcome | #835 |
| cases follow | #835 |
| pachymetry | #840 |
| individuals patients | #841 |
| patients operation | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| exhaust | #848 |
| 2 weeks treatment | #848 |
| levels air | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| cell area | #855 |
| purpose prospectively | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| inhibitors diclofenac | #861 |
| myopic eyes | #861 |
| thiazolidines | #865 |
| histamine h1 | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| 01 compared | #874 |
| patients eyes | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| evaluation early | #880 |
| h1 antagonists | #880 |
| benzamidine | #880 |
| patient comfort | #881 |
| cells contributes | #882 |
| assessing efficacy | #882 |
| diseases background | #883 |
| study eye | #886 |
| patients condition | #887 |
| bleb | #887 |
| specular | #890 |
| respiratory syncytial | #894 |
| 114 years | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| decreased baseline | #905 |
| benzophenones | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| treatment symptoms | #928 |
| 8 males | #928 |
| epithelial lesions | #929 |
| immunoregulatory effects | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| beta1 tumor | #937 |
| epithelialization | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| cytokines epithelial | #941 |
| symptoms evaluated | #941 |
| normal 1 | #943 |
| humans muscarinic | #946 |
| factor production | #946 |
| wheal | #947 |
| mgd | #949 |
| radioallergosorbent test | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| scanning confocal | #957 |
| 2 moderate | #957 |
| singleagent therapy | #959 |
| 3 eyes | #959 |
| aldose | #959 |
| endpoint baseline | #960 |
| intracellular infection | #961 |
| sedating | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| term therapeutic | #973 |
| basal epithelial | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| observed conclusions | #994 |
| tenon | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| observed vivo | #1002 |
| methods sixteen | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| blink | #1017 |
| 1 2 weeks | #1017 |
| impression | #1019 |
| normal volunteers | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| patching | #1040 |
| 045 ± | #1040 |
| webbased questionnaire | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| lysine 4 | #1044 |
| cells fibroblasts | #1044 |
| concomitantly | #1045 |
| treatment skin | #1045 |
| xerophthalmia | #1046 |
| indirect humans | #1050 |
| recurrence 6 | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| disposable | #1067 |
| pollution risk | #1067 |
| staphylococcal enterotoxin | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| months corrected | #1075 |
| effective treating | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| syncytial virus | #1080 |
| ade | #1080 |
| techniques ophthalmological | #1080 |
| allergic inflammatory | #1082 |
| expression icam1 | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| diseases objective | #1104 |
| assessed vivo | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| lens capsule | #1116 |
| rose | #1116 |
| 30 patients | #1118 |
| keratopathy | #1121 |
| drops | #1121 |
| popularization | #1122 |
| 92 years | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| assay fibroblasts | #1133 |
| cultures human | #1133 |
| clinical findings | #1133 |
| treatment objective | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| visual acuities | #1140 |
| healthy eyes | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| p0035 | #1146 |
| 4 daily | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| cornea | #1173 |
| glands sjogren | #1173 |
| immune mechanisms | #1189 |
| fibronectins fibrosis | #1189 |
| ophthalmological female | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| concentrations alpha | #1210 |
| 84 ± | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| study eyes | #1286 |
| aged substance | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| higher severe | #1316 |
| chemokines chemotaxis | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| 830 | #1322 |
| ccl11 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| 18 eyes | #1399 |
| female glucocorticoids | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| proteaseactivated receptor | #1413 |
| diseases diagnosis | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| haze | #1444 |
| corneal neovascularization | #1444 |
| temperature cell | #1445 |
| reduced 1 | #1451 |
| goblet cells | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| studies suture | #1502 |
| bulbar | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| ortho aminobenzoates | #1602 |
| preservative | #1602 |
| cells 0001 | #1603 |
| vdt | #1624 |
| humans intraocular | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| 10 healthy controls | #1663 |
| syncytial | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| outcome visual | #1713 |
| disease defined | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| central corneal | #1741 |
| cytology | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| japan methods | #1823 |
| receptor par2 | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| 15 minutes | #1828 |
| eosinophil | #1828 |
| child dermatitis | #1832 |
| epithelial damage | #1835 |
| mediator release | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| ari | #1862 |
| tnfalpha production | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| cataract surgery | #1893 |
| aphakia | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| protein female | #1946 |
| severe persistent | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 5 minutes | #1970 |
| 9 males | #1970 |
| 4 males | #1971 |
| comfort | #1972 |
| device treatment | #1972 |
| gpc | #1974 |
| corrected visual | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| agents male | #2023 |
| tacrolimus adult | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| allergens animals | #2067 |
| ambient air pollution | #2067 |
| versus normal | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| docosahexaenoic acid | #2137 |
| endopeptidases serine | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| curve reproducibility | #2164 |
| production inhibited | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| aged mitomycin | #2192 |
| diseases female | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| rater agreement | #2246 |
| vital | #2246 |
| pollens | #2247 |
| scores correlated | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| ophthalmology | #2415 |
| aged nitrogen | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| fungal female | #2498 |
| enteric coated | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| oct | #2571 |
| methods clinical | #2571 |
| male polymerase | #2573 |
| flare | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| postsurgical | #2629 |
| eosinophilia female | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| bf | #2698 |
| tearing | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| anterior chamber | #2907 |
| test performed | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| measured elisa | #3014 |
| eosinophils humans | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| expression adhesion | #3132 |
| rtpcr | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| symptom scores | #3181 |
| cell count | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| vegf mrna | #3694 |
| disease adolescent | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| adult air | #3751 |
| suture techniques | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| management disease | #3773 |
| helper type | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| chemokines | #3992 |
| microscopy | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| papillary | #4193 |
| α induced | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| months treatment | #5023 |
| nitrogen dioxide | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| thirtysix patients | #5224 |
| epithelium | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| th2 cells | #5747 |
| grades | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| house dust | #6543 |
| rejection humans | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| linked immunosorbent | #6618 |
| glucocorticoids humans | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| humans japan | #6704 |
| months compared | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| complaints | #9098 |
| 3 6 | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| 4 weeks | #13267 |
| epithelia | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| alkylating | #18391 |
| stained | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Key People For Allergic Conjunctivitis
Top KOLs in the world
Hiroshi Fujishima:Expert Impact
Concepts for whichHiroshi Fujishimahas direct influence:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:KOL impact
Concepts related to the work of other authors for whichfor which Hiroshi Fujishima has influence:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |